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EXECUTIVE SUMMARY
Background
WHO estimates that in 2015, 71 million persons were living with chronic 
hepatitis C virus (HCV) infection worldwide and that 399 000 died from cirrhosis 
or hepatocellular carcinoma caused by HCV infection. In May 2016, the World 
Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral 
hepatitis, which proposes to eliminate viral hepatitis as a public health threat by 
2030 (90% reduction in incidence and 65% reduction in mortality). Elimination 
of viral hepatitis as a public health threat requires 90% of those infected to be 
diagnosed and 80% of those diagnosed to be treated. 
Rationale
Since the last update to the Guidelines was issued in 2016, three key 
developments have prompted changes in terms of when to treat and what 
treatments to use. First, the use of safe and highly effective direct-acting 
antiviral (DAA) regimens for all persons improves the balance of benefits and 
harms of treating persons with little or no fibrosis, supporting a strategy of 
treating all persons with chronic HCV infection, rather than reserving treatment 
for persons with more advanced disease. Second, since 2016, several new, 
pangenotypic DAA medicines have been approved by at least one stringent 
regulatory authority, reducing the need for genotyping to guide treatment 
decisions. Third, the continued substantial reduction in the price of DAAs 
has enabled treatment to be rolled out rapidly in a number of low- and middle-
income countries.
Scope
These guidelines aim to provide evidence-based recommendations on the care 
and treatment of persons diagnosed with chronic HCV infection. They update 
the care and treatment section of the WHO Guidelines for the screening, 
care and treatment of persons with hepatitis C infection issued in April 2016. 
The 2017 Guidelines on hepatitis B and C testing update the screening section. 
xiii
Audience
These guidelines are intended for government officials to use as the basis for 
developing national hepatitis policies, plans and treatment guidelines. These 
include country programme managers and health-care providers responsible 
for planning and implementing hepatitis care and treatment programmes, 
particularly in low- and middle-income countries. 
Methods
WHO developed these guidelines in accordance with procedures established 
by its Guidelines Review Committee. Systematic reviews were undertaken to 
assess the safety and efficacy of treatment regimens in adults, to examine the 
morbidity and mortality from extrahepatic manifestations in persons with HCV 
infection and to review the literature on cost–effectiveness. In addition, modelling 
was carried out. A regionally representative and multidisciplinary Guidelines 
Development Group met in September 2017 to formulate the recommendations, 
using the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) approach. This included an assessment of the quality of evidence 
(high, moderate, low or very low), consideration of the overall balance of benefits 
and harms (at individual and population levels), patient/health worker values and 
preferences, resource use, cost–effectiveness, and consideration of feasibility 
and effectiveness across a variety of resource-limited settings. 
Summary of the new recommendations
When to start treatment in adults and adolescents
1 With the exception of pregnant women
WHO recommends offering treatment to all individuals diagnosed with HCV infection  
who are 12 years of age or older,1 irrespective of disease stage (Strong recommendation, 
moderate quality of evidence)
xiv
What treatment to use for adults and adolescents
2  The Guidelines Development Group defined pangenotypic regimens as those leading to a SVR 
rate >85% across all six major HCV genotypes. 
3  Persons with HCV genotype 3 infection who have received interferon and/or ribavirin in the past 
should be treated for 16 weeks.
4  May be considered in countries where genotype distribution is known and genotype 3 prevalence 
is <5%.
WHO recommends the use of pangenotypic DAA regimens for the treatment of persons 
with chronic HCV infection aged 18 years and above.2 
(Conditional recommendation, moderate quality of evidence)
In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV infection, 
WHO recommends:
• sofosbuvir/ledipasvir for 12 weeks in genotypes 1, 4, 5 and 6
• sofosbuvir/ribavirin for 12 weeks in genotype 2
• sofosbuvir/ribavirin for 24 weeks in genotype 3.
(Strong recommendation/very low quality of evidence)
Pangenotypic regimens currently available for use in adults 18 years of 
age or older
For adults without cirrhosis, the following pangenotypic regimens can be used: 
• Sofosbuvir/velpatasvir 12 weeks
• Sofosbuvir/daclatasvir 12 weeks
• Glecaprevir/pibrentasvir 8 weeks3 
For adults with compensated cirrhosis, the following pangenotypic regimens can 
be used:
• Sofosbuvir/velpatasvir 12 weeks
• Glecaprevir/pibrentasvir 12 weeks3
• Sofosbuvir/daclatasvir 24 weeks
• Sofosbuvir/daclatasvir 12 weeks4
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Treatment of children 0–12 years of age
5  Prior to approval of DAAs for children aged <12 years of age, exceptional treatment with 
interferon + ribavirin may be considered for children with genotype 2 or 3 infection and severe 
liver disease. This may include children at higher risk of progressive disease, such as with HIV 
coinfection, thalassaemia major and survivors of childhood cancer.
In children aged less than 12 years with chronic HCV infection, WHO recommends:
•  deferring treatment until 12 years of age 
(conditional recommendation, very low quality of evidence) 
•  treatment with interferon-based regimens should no longer be used 
(strong recommendation, very low quality of evidence)5
Clinical considerations
General clinical considerations
•  The use of pangenotypic regimens obviates the need for genotyping before 
treatment initiation.
•  In resource-limited settings, WHO recommends that the assessment of liver 
fibrosis should be performed using non-invasive tests (e.g. aspartate/platelet 
ratio index (APRI) score or FIB-4 test, see existing recommendations, p. xvii). 
This can determine if there is cirrhosis before initiation of treatment.
•  There are a few contraindications to using pangenotypic DAAs together with 
other medicines.
•  DAAs are well tolerated, with only minor side-effects. Therefore, the frequency 
of routine laboratory toxicity monitoring can be limited to a blood specimen at 
the start and end of treatment.
•  Following completion of DAA treatment, sustained virological response (SVR) at 
12 weeks after the end of treatment is used to determine treatment outcomes 
(See existing recommendations, p. xvii).
HIV/HCV coinfection
•  Persons with HIV/HCV coinfection are at a higher risk for progression of fibrosis 
and were included in the list of persons prioritized for treatment since the 2014 
WHO treatment guidelines. Treatment for HCV infection needs to consider 
drug–drug interactions with antiretroviral medications.
HBV/HCV coinfection
•  Persons with HBV/HCV coinfection are at risk for HBV reactivation during and 
following HCV treatment. An assessment for HBV treatment eligibility with 
initiation of HBV treatment for those eligible may prevent HBV reactivation 
during HCV treatment.
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Cirrhosis
•  Persons with cirrhosis, including those who have achieved SVR, may be 
regularly screened for hepatocellular carcinoma (HCC). 
Chronic kidney disease
•  Data are insufficient on the safety and efficacy of sofosbuvir-based regimens 
in persons with severe renal impairment. Glecaprevir/pibrentasvir is effective 
against infection with all six major genotypes in persons with chronic 
kidney disease.
TB/HCV coinfection
•  In persons with TB/HCV coinfection, treatment for active TB is considered 
before treatment of HCV infection. TB/HCV-coinfected persons treated for TB 
are at an increased risk of hepatotoxicity.
Retreatment after DAA treatment failure 
•  Currently, only one pangenotypic DAA regimen, sofosbuvir/velpatasvir/
voxilaprevir, is approved by a stringent regulatory authority for the retreatment 
of persons who have previously failed DAA treatment.
•  Investigations of a failure to achieve SVR with DAA therapy includes 
re-examination of adherence and of potential drug–drug interactions.
Simplified service delivery models
An eight-point approach to service delivery supports implementation of the clinical 
recommendations for Treat All and adoption of pangenotypic DAA regimens:
1. Comprehensive national planning for the elimination of HCV infection;
2. Simple and standardized algorithms across the continuum of care;
3. Integration of hepatitis testing, care and treatment with other services; 
4. Strategies to strengthen linkage from testing to care, treatment and prevention;
5. Decentralized services, supported by task-sharing; 
6.  Community engagement and peer support to address stigma and discrimination, 
and reach vulnerable or disadvantaged communities; 
7. Efficient procurement and supply management of medicines and diagnostics;
8. Data systems to monitor the quality of individual care and the cascade of care. 
Public health considerations in specific populations
Five population groups (people who inject drugs [PWID], people in prisons or 
other closed settings, men who have sex with men, sex workers and indigenous 
populations) require specific public health approaches because of one or more of the 
following specific issues: high incidence, high prevalence, stigma, discrimination, 
criminalization or vulnerability, and difficulties in accessing services.
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Who to test for HCV infection? (2017 testing guidelines) (3)
1. Focused testing in most-affected populations. In all settings (and regardless of whether 
delivered through facility- or community-based testing), it is recommended that serological 
testing for HCV antibody (anti-HCV)1 be offered with linkage to prevention, care and treatment 
services to the following individuals:
•  Adults and adolescents from populations most affected by HCV infection2 (i.e. who are 
either part of a population with high HCV seroprevalence or who have a history of exposure 
and/or high-risk behaviours for HCV infection);
•  Adults, adolescents and children with a clinical suspicion of chronic viral hepatitis3  
(i.e. symptoms, signs, laboratory markers).
(Strong recommendation, low quality of evidence)
Note: Periodic retesting using HCV nucleic acid tests (NAT) should be considered for those 
with ongoing risk of acquisition or reinfection.
2. General population testing. In settings with a ≥2% or ≥5%4 HCV antibody seroprevalence 
in the general population, it is recommended that all adults have access to and be offered 
HCV serological testing with linkage to prevention, care and treatment services. 
General population testing approaches should make use of existing community- or facility- 
based testing opportunities or programmes such as HIV or TB clinics, drug treatment  
services and antenatal clinics.5 
(Conditional recommendation, low quality of evidence)
3. Birth cohort testing. This approach may be applied to specific identified birth cohorts of 
older persons at higher risk of infection6 and morbidity within populations that have an overall 
lower general prevalence.
(Conditional recommendation, low quality of evidence)
Summary of the existing WHO recommendations
1 This may include fourth-generation combined antibody/antigen assays.
2  Includes those who are either part of a population with higher seroprevalence (e.g. some mobile/
migrant populations from high/intermediate endemic countries, and certain indigenous populations) 
or who have a history of exposure or high-risk behaviours for HCV infection (e.g. PWID, people in 
prisons and other closed settings, men who have sex with men and sex workers, and HIV-infected 
persons, children of mothers with chronic HCV infection especially if HIV-coinfected).
3  Features that may indicate underlying chronic HCV infection include clinical evidence of existing liver 
disease, such as cirrhosis or hepatocellular carcinoma (HCC), or where there is unexplained liver 
disease, including abnormal liver function tests or liver ultrasound.
4  A threshold of ≥2% or ≥5% seroprevalence was based on several published thresholds of intermediate 
and high seroprevalence. The threshold used will depend on other country considerations and 
epidemiological context.
5  Routine testing of pregnant women for HCV infection is currently not recommended.
6  Because of historical exposure to unscreened or inadequately screened blood products and/or poor 
injection safety.
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How to test for chronic HCV infection and monitor treatment response? (2017  
testing guidelines) (3)
1. Which serological assay to use? To test for serological evidence of past or present  
infection in adults, adolescents and children (>18 months of age),1 an HCV serological assay 
(antibody or antibody/antigen) using either a rapid diagnostic test (RDT) or laboratory-based 
immunoassay formats2 that meet minimum safety, quality and performance standards3  
(with regard to both analytical and clinical sensitivity and specificity) is recommended. 
•  In settings where there is limited access to laboratory infrastructure and testing, and/or in 
populations where access to rapid testing would facilitate linkage to care and treatment, 
RDTs are recommended.
(Strong recommendation, low/moderate quality of evidence)
2. Serological testing strategies. In adults and children older than 18 months, a single serolo-
gical assay for initial detection of serological evidence of past or present infection is recommen-
ded prior to supplementary nucleic acid testing (NAT) for evidence of viraemic infection.
(Conditional recommendation, low quality of evidence)
3. Detection of viraemic infection
•  Directly following a reactive HCV antibody serological test result, the use of quantitative or 
qualitative NAT for detection of HCV RNA is recommended as the preferred strategy  
to diagnose viraemic infection.
(Strong recommendation, moderate/low quality of evidence)
•  An assay to detect HCV core (p22) antigen, which has comparable clinical sensitivity to 
NAT, is an alternative to NAT to diagnose viraemic infection.
(Conditional recommendation, moderate quality of evidence)4 
4. Assessment of HCV treatment response
•  Nucleic acid testing for qualitative or quantitative detection of HCV RNA should be used as 
the test of cure at 12 or 24 weeks (i.e. sustained virological response [SVR12 or SVR24]) 
after completion of antiviral treatment.
(Conditional recommendation, moderate/low quality of evidence)
1  HCV infection can be confirmed in children under 18 months only by virological assays to detect HCV RNA, because 
transplacental maternal antibodies remain in the child’s bloodstream up until 18 months of age, making test results 
from serology assays ambiguous.
2  Laboratory-based immunoassays include enzyme immunoassay (EIA), chemoluminescence immunoassay (CLIA) and 
electrochemoluminescence assay (ECL).
3  Assays should meet minimum acceptance criteria of either WHO prequalification of in vitro diagnostics (IVDs) or a 
stringent regulatory review for IVDs. All IVDs should be used in accordance with manufacturers’ instructions, and 
where possible at testing sites enrolled in a national or international external quality assessment scheme.
4  A lower level of analytical sensitivity can be considered if an assay is able to improve access (i.e. an assay that can be 
used at the point of care or is suitable for dried blood spot [DBS] specimens) and/or affordability. An assay with a limit 
of detection of 3000 IU/mL or lower would be acceptable and would identify 95% of those with viraemic infection, 
based on the available data.
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Screening for alcohol use and counselling to reduce moderate and high levels of alcohol 
intake (2016 treatment guidelines) (2)
An alcohol intake assessment is recommended for all persons with HCV infection followed  
by the offer of a behavioural alcohol reduction intervention for persons with moderate-to- 
high alcohol intake.
(Strong recommendation, moderate quality of evidence)
Assessing degree of liver fibrosis and cirrhosis (2016 treatment guidelines) (2)
In resource-limited settings, it is suggested that the aminotransferase/platelet ratio index 
(APRI) or FIB-4 tests be used for the assessment of hepatic fibrosis rather than other  
non-invasive tests that require more resources such as elastography or FibroTest.
(Conditional recommendation, low quality of evidence)
xx
Summary algorithm for the diagnosis, treatment and monitoring  
of chronic HCV infection in adults and adolescents
* Persons with HCV genotype 3 infection who have received interferon and/or ribavirin in the past should be treated for 
16 weeks. 
** May be considered in countries where genotype distribution is known and genotype 3 prevalence is <5%. 
*** Treatment in adolescents at this time still requires genotyping to identify the appropriate regimen. 
AFP: alpha fetoprotein, APRI: aspartate-to-platelet ratio index, FIB-4: fibrosis stage 
• Assess cure: sustained virological response (SVR) at 12 weeks after the end of treatment 
 (HCV RNA SVR, qualitative or quantitative nucleic acid test [NAT])
• Detection of hepatocellular carcinoma (HCC) in persons with cirrhosis (every 6 months) 
 with ultrasound or AFP 
≥18 YEARS WITHOUT CIRRHOSIS 
•  Sofosbuvir/velpatasvir 12 weeks
•  Sofosbuvir/daclatasvir 12 weeks
•  Glecaprevir/pibrentasvir 8 weeks*
ADOLESCENTS (12–17 YEARS)*** 
•  Sofosbuvir/ledipasvir 12 weeks in genotypes 1, 4, 5 and 6
•  Sofosbuvir/ribavirin 12 weeks in genotype 2
•  Sofosbuvir/ribavirin 24 weeks in genotype 3
≥18 YEARS WITH COMPENSATED CIRRHOSIS 
•  Sofosbuvir/velpatasvir 12 weeks
•  Glecaprevir/pibrentasvir 12 weeks*
•  Sofosbuvir/daclatasvir 24 weeks
•  Sofosbuvir/daclatasvir 12 weeks**
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CONDUCT ANTI-HCV ANTIBODY TESTING 
Use rapid diagnostic test or laboratory-based immunoassay
START TREATMENT
The following should be assessed prior to treatment initiation
•  Assess liver fibrosis with non-invasive testing, e.g. APRI, FIB-4 to determine if there is cirrhosis
•  Assess other considerations for treatment (comorbidities, pregnancy, potential drug–drug interactions)
PROCEED TO SUPPLEMENTARY TESTING 
Use HCV RNA (qualitative or quantitative) or HCV core antigen (cAg)
 
3
4
1
2
Anti-HCV +
HCV RNA test – or cAg-HCV RNA test + or cAg+
No HCV infectionHCV infection
CHAPTER 1. SCOPE AND OBJECTIVES
1.1 Objectives
The objective of these guidelines is to provide updated evidence-based 
recommendations on the care and treatment of persons with chronic hepatitis 
C virus (HCV) infection in terms of when to treat and what treatment to use in 
children, adolescents and adults.
1.2 New developments and rationale for an update of 
the guidelines
In 2014, WHO published its first Guidelines for the screening, care and treatment 
of persons with HCV infection (1). The care and treatment component of the 
2014 Guidelines were updated a first time in 2016 (2) and a second time with the 
present guidelines. In parallel, the 2017 Guidelines on testing for viral hepatitis 
recommended which approaches to use in terms of who to test and how to 
test (3).
The 2016 Guidelines for the screening, care and treatment of persons with HCV 
infection recommended DAA regimens for the treatment of persons with HCV 
infection (2). While all HCV-infected persons could be considered for treatment, 
the Guidelines also highlighted key factors to consider in prioritizing treatment 
(i) for those likely to derive the greatest individual benefit, or (ii) in populations 
deriving the greatest treatment benefit from limiting HCV transmission. Those with 
the highest risk of mortality and morbidity include those at risk of accelerated 
fibrosis, metabolic syndrome and extrahepatic manifestations. Those for whom 
treatment could lead to a reduction in incidence included PWID, HIV-infected 
MSM, prisoners, sex workers and health-care workers.
Since the 2016 Guidelines for the screening, care and treatment of persons with 
HCV infection, three key developments prompted changes in terms of when to 
treat and what treatment to use:
1.  The generalized use of safe and highly effective direct-acting antiviral 
(DAA) medicine regimens for all persons improves the balance of benefits 
to harms of treating persons with little or no fibrosis, supporting a strategy of 
treating all persons with chronic HCV infection, rather than reserving treatment 
for persons with more advanced disease. Prior to 2014, HCV treatment 
involved the use of interferon-based regimens with generally low rates of cure, 
long duration of therapy and substantial toxicities. The introduction of highly 
2effective and well tolerated short-course oral DAA therapy that can cure HCV 
infection with high rates of sustained virological response (SVR) within weeks 
transformed the treatment landscape for persons with chronic HCV infection. 
Since the 2016 Guidelines, DAA regimens have continued to improve.
2.  Several new, pangenotypic DAA medicines have been approved by at least 
one stringent regulatory authority, reducing the need for genotyping to guide 
treatment decisions. Pangenotypic DAA combination regimens approved by the 
United States Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) include sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir 
and glecaprevir/pibrentasvir. These regimens achieve high treatment efficacy 
across all six major HCV genotypes, including in those with cirrhosis or 
HIV coinfection. In addition, the Guidelines Development Group considered 
sofosbuvir/daclatasvir, commonly used in LMICs, as a pangenotypic regimen, 
based on all the available evidence from clinical trials and observational studies 
in different settings.
3.  The continued substantial reduction in the price of DAA regimens has 
enabled treatment to be rolled out rapidly in a number of low- and middle-
income countries (LMICs) (4).
Together, these three factors have shifted the balance of benefits and risks in favour 
of treating all persons with chronic HCV infection with pangenotypic regimens. 
1.3 Target audience
Although the recommendations included in these guidelines apply to all countries, 
the key audience for these guidelines is policy-makers in ministries of health in 
LMICs. The recommendations are intended for government officials to use as the 
basis for developing national hepatitis policies, plans and treatment guidelines. 
For countries with existing national plans/programmes, these guidelines can 
guide updates of national hepatitis treatment guidelines and for deciding which 
medicines to use. In addition, implementing partners can use the guidelines to 
inform the design and implementation of treatment services. The guidelines are 
also intended to be helpful for clinicians who treat HCV-infected persons.
1.4 Scope of the guidelines
The recommendations in these guidelines address treatment issues. However 
recommendations related to prevention, testing and care are referred to in order 
to reinforce the importance of the continuum of care (including identification 
of infected persons) that is a key element of the clinical management of HCV 
infection. The management of acute HCV infection was not included in the scope 
of work for these guidelines.
31.5 Related guidelines
These guidelines are intended to complement existing guidance on the primary 
prevention of HCV and other bloodborne viruses by improving blood and injection 
safety, and health care for people who inject drugs (PWID) and other vulnerable 
groups, including those living with HIV.
Additional guidance relevant to the prevention, care and treatment of those 
infected with HCV can be found in the following documents:
•  Consolidated guidelines on HIV prevention, diagnosis, treatment and care for 
key populations. Geneva: WHO; 2016 update (5)
•  Guidelines for the prevention, care and treatment of persons with hepatitis B 
infection. Geneva: WHO; 2015 (6) 
•  WHO guideline on the use of safety-engineered syringes for intramuscular, 
intradermal and subcutaneous injections in health-care settings. Geneva: 
WHO; 2016 (7)
•  Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection. Geneva: WHO; 2016 (8)
•  Guidelines on hepatitis B and C testing. Geneva: WHO; 2017 (3)
1.6 Guiding principles
The following principles have informed the development of these guidelines and 
should guide the implementation of the recommendations.
•  The guidelines will contribute to realizing the Sustainable Development Goals 
through achieving key global and national hepatitis goals.
•  The guidelines are based on a public health approach to scaling up the use of 
antiviral treatment for HCV infection along the continuum of hepatitis prevention, 
care and treatment.
•  Implementation of the guidelines need to be accompanied by efforts to promote 
and protect the human rights of people who need hepatitis services, including 
ensuring informed consent, preventing stigma and discrimination in the 
provision of services and promoting gender equity.
•  Implementation of the recommendations in these guidelines should be 
informed by local context, including HCV epidemiology and prevalence of other 
comorbidities, availability of resources, the organization and capacity of the 
health system and anticipated cost–effectiveness.
CHAPTER 2. BACKGROUND
2.1 The challenge of HCV elimination 
WHO estimated that in 2015, 71 million persons were living with chronic HCV 
infection worldwide (global prevalence: 1%) and that 399 000 had died from 
cirrhosis or hepatocellular carcinoma (HCC) (9). Aside from the burden of HCV 
infection secondary to liver-related sequelae, HCV causes an additional burden 
through comorbidities among persons with HCV infection, including depression, 
diabetes mellitus and chronic renal disease. A proportion of these morbidities 
is directly attributable to HCV and is therefore referred to as extrahepatic 
manifestations. These manifestations are likely to be affected by treatment 
(see Chapter 4 and Fig. 2.2). The World Health Assembly recognized that viral 
hepatitis is a major public health problem and passed two initial resolutions in 
2010 (10) and 2014 (11).
WHO estimated that in 2015, 1.75 million new HCV infections occurred, mostly 
because of injecting drug use and unsafe health care (9). Worldwide, HCV infection 
may be caused by one of six major HCV genotypes (Fig. 2.1) (12). However, 
in many countries, the genotype distribution remains unknown (13). 
FIG. 2.1 Worldwide distribution of HCV genotypes
Source: The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus 
infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76. 
Disclaimer: This map is reproduced as originally published.
5In May 2016, the World Health Assembly endorsed the Global Health Sector 
Strategy (GHSS) for 2016–2021 on viral hepatitis (HBV and HCV infection), which 
proposes to eliminate viral hepatitis as a public health threat by 2030. Elimination 
is defined as a 90% reduction in new chronic infections and a 65% reduction 
in mortality compared with the 2015 baseline (14). To reach these targets, the 
GHSS recommends scaling up currently available prevention interventions and 
introducing newer programmatic components, such as testing and treatment. 
Elimination of HCV infection as a public health threat requires diagnosing 90% 
of those infected and treating 80% of those diagnosed. However, in 2015, there 
were large deficits in achieving these service coverage objectives. Of the 71 million 
persons with HCV infection, 14 million (20%) had been diagnosed (a 70% gap), 
and of the 14 million diagnosed, 1.1 million (7%) had been started on treatment 
(a 73% gap) (9).
2.1.1 Natural history of HCV infection 
Hepatitis 
HCV infection causes both acute and chronic hepatitis. Incident infection is 
associated with early symptoms in about 20% of persons. Spontaneous clearance 
occurs within six months of infection in 15–45% of infected individuals in the 
absence of treatment. The remaining 55–85% develop chronic infection, which 
can lead to progressive fibrosis and cirrhosis. The risk of cirrhosis ranges from 
15% to 30% after 20 years of infection with HCV (15–17). Initially, cirrhosis 
may be compensated. Decompensation may occur later, leading to variceal 
haemorrhages, ascites or encephalopathy (18). Each year, approximately 1–3% of 
persons with cirrhosis progress to hepatocellular carcinoma (HCC) (19). The risk 
of progression to cirrhosis and HCC varies according to the person’s characteristics 
and behaviours. Alcohol use, HBV or HIV coinfection and immunosuppression 
due to any cause increase the risk of developing cirrhosis or HCC (20). 
Extrahepatic manifestations
HCV infection can lead to extrahepatic manifestations (21). Among HCV-infected 
persons, the three most common comorbidities are depression (24%), diabetes 
mellitus (15%) and chronic renal disease (10%). A proportion of these morbidities 
is directly attributable to HCV and is therefore referred to as extrahepatic 
manifestations (Fig. 2.2). Extrahepatic manifestations are likely to be affected by 
treatment (in red in Fig. 2.2, for example, only 37% of diabetes among HCV-
infected persons would be attributable to HCV infection). The prevalence of these 
extrahepatic manifestations is usually independent of the degree of liver fibrosis 
(22, 23). 
62.1.2 Natural history of HIV/HCV coinfection
Coinfection with HIV adversely affects the course of HCV infection. Coinfected 
persons, particularly those with advanced immunodeficiency (CD4 count <200 
cells/mm3), have significantly accelerated progression to cirrhosis, decompensated 
cirrhosis and HCC compared to HCV-monoinfected persons (24–26). In high-
income countries (HICs), HCV-associated liver disease has become a leading 
cause of death in people living with HIV, accounting for almost half (47%) of 
the deaths in the United States (27, 28). It is unclear whether HCV infection 
accelerates HIV disease progression, but after initiation of antiretroviral therapy 
(ART), CD4 recovery is impaired in HIV/HCV-coinfected persons when compared 
to those with HIV monoinfection (29, 30). HIV/HCV-coinfected persons have 
demonstrated more rapid HIV disease progression compared to those who were 
HIV-infected alone in some but not all studies (31–33). Assessment of the impact 
of HCV infection on HIV disease progression may be confounded by the negative 
health consequences of injecting drug use, which is strongly associated with 
HCV infection (34, 35). In persons with HIV coinfection, HCC tends to occur at a 
younger age and within a shorter time period (36, 37).
FIG. 2.2 Prevalence of comorbidities among persons with HCV infection, including the fraction 
that is attributable to HCV infection (calculated on the basis of Younossi et al. 2016, using 
attributable fractions among those exposed) 
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72.1.3 Routes of transmission 
Health-care-associated transmission
In countries where infection control measures are insufficient, HCV infection 
is associated with unsafe injection practices and procedures such as renal dialysis, 
surgery, dental care and unscreened blood transfusions (38–41). Worldwide, 
in 2010, 5% of health-care injections were given with unsterilized, reused 
injection devices (42) and unsafe injections were estimated to lead to 315 000 
new HCV infections each year (43). In addition, excessive use of injections to 
administer medications is a matter of concern (44). Coupled with poor injection 
practices, overuse of injections further increases HCV transmission. This 
persisting driver of transmission needs to be addressed through safer health care, 
introduction of reuse-prevention devices (45) and a reduction in unnecessary 
health-care injections.
Transmission among people who inject drugs
Globally, injection drug use may account for 23% of new HCV infections; 8% 
of current HCV infections are among PWID (9). PWID infected with HCV are at 
increased risk of all-cause mortality, reflecting the combined role of injecting drug 
use, low socioeconomic status, poor access to health care and environmental 
factors (46, 47).
Other modes of transmission
Other modes of HCV transmission include mother-to-child transmission, which 
affects 4–8% of children born to women with HCV infection and 10.8–25% of 
children born to women with HIV/HCV coinfection (48), other percutaneous 
procedures, such as tattooing and body piercing (49), and needlestick injuries 
in health-care workers (50, 51). Sexual transmission of HCV occurs infrequently 
in heterosexual couples. However, it is more frequent in HIV-positive persons, 
particularly in men who have sex with men (MSM) (52).
82.2 Direct-acting antivirals
As of May 2018, the FDA or the EMA had approved 13 direct-acting antivirals from 
four classes (see Table 2.1), and several fixed-dose combination (FDC) DAAs for 
the treatment of persons with HCV infection. 
2.2.1 Summary of the currently available pangenotypic DAA 
combinations
DAAs are considered pangenotypic when they achieve high treatment efficacy 
across all six major HCV genotypes. 
Sofosbuvir/velpatasvir
Sofosbuvir/velpatasvir is an FDC of a pangenotypic NS5A inhibitor and sofosbuvir. 
It was approved both by the FDA and EMA in 2016. In clinical trials, it is associated 
with good efficacy in infections with genotypes 1–6, HIV/HCV coinfection, 
persons on opioid substitution therapy (OST) and persons with compensated 
or decompensated cirrhosis (53–57). 
Sofosbuvir/velpatasvir/voxilaprevir 
Sofosbuvir/velpatasvir/voxilaprevir is generally considered for use in the retreatment 
of HCV-infected persons who previously failed a DAA regimen (see also section 
5.2.6 on retreatment of persons with DAA failure); however, in some HICs it is also 
registered for treatment-naive HCV-infected persons.
TABLE 2.1 Direct-acting antivirals (DAAs) according to class
NS3/4A (protease) 
inhibitors
NS5A  
inhibitors
NS5B polymerase inhibitor 
(nucleotide analogue) 
NS5B polymerase inhibitor 
(non-nucleoside analogue)
Glecaprevir Daclatasvir Sofosbuvir Dasabuvir
Voxilaprevir Velpatasvir
Grazoprevir Ledipasvir
Paritaprevir Ombitasvir
Simeprevir Pibrentasvir
Elbasvir
9Glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir is an FDC containing a pangenotypic NS3/4A protease 
inhibitor with a pangenotypic NS5A inhibitor that was approved by the FDA and 
EMA in 2017. In clinical trials, glecaprevir/pibrentasvir suggest good efficacy in 
infections with genotypes 1–6, compensated cirrhosis, including in persons with 
renal insufficiency and end-stage renal disease (58–64). It is contraindicated in 
persons with decompensated cirrhosis (Child–Pugh Class C). 
Sofosbuvir/daclatasvir 
Daclatasvir, an NS5A inhibitor that has been evaluated with sofosbuvir, was 
approved by the EMA in 2014 and by the FDA in 2015. Clinical trials reported 
good efficacy of the combination of daclatasvir and sofosbuvir in infections 
with genotypes 1–4, persons with decompensated liver disease, liver transplant 
recipients and those with HIV/HCV coinfection (65–68). Recent data suggest 
that the combination of sofosbuvir/daclatasvir is also effective in infections with 
genotypes 5 and 6 (69) (Médecins Sans Frontières [MSF] demonstration project, 
manuscript in preparation).
Other DAA regimens
Additional evidence being generated may indicate in the future that other DAA 
regimens (e.g. sofosbuvir/ravidasvir) are pangenotypic or that existing pangenotypic 
DAA regimens can be used in more populations (e.g. children and adolescents 
<18 years of age). 
2.3 Access to direct-acting antivirals 
DAAs for HCV infections have been initially sold at a very high price, limiting access. 
Opportunities to access low-price generic medicines are increasing, particularly in 
LMICs (4). (See Strategies for more efficient procurement and supply management 
of medicines and diagnostics in section 6.7, Table 6.2.)
CHAPTER 3. METHODS
3.1 WHO guidelines development process
These WHO guidelines were produced by following the recommendations 
for standard guidelines, as described in the WHO Handbook for guideline 
development (70). The Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) framework was followed (71). A WHO Steering Committee 
was constituted, which included individuals with relevant expertise from 
different WHO departments. This Committee oversaw the entire guidelines 
development process. 
A Guidelines Development Group was constituted to ensure representation from 
various stakeholder groups, including members of organizations that represent 
patients’ groups, advocacy groups, researchers and clinicians. Group members 
were also selected to achieve geographical representation and gender balance.
Systematic reviews were undertaken to assess the safety and efficacy of treatment 
regimens in adults and children, to examine the morbidity and mortality from 
extrahepatic manifestations in persons with HCV infection and to review the 
literature on cost–effectiveness. In addition, modelling was carried out. Outcomes 
were ranked by the Guidelines Development Group based on their importance to 
the patient population. Members of the Group met in Geneva in September 2017.
3.2 Formulation of recommendations
At the Guidelines Development Group meeting, the results of the systematic reviews, 
meta-analyses and complementary information were presented, and the evidence 
profiles and decision-making tables were reviewed to ensure that there was 
understanding and agreement on the scoring criteria. See Web annexes 3.1, 3.2 
and 8 for the reviews and Web annexes 1, 2 and 6 for the decision-making tables. 
The GRADE method was used to rate the certainty of the evidence and determine 
the strength of the recommendations. The strength of the recommendations 
was rated as either strong (the panel was confident that the desirable effects of 
the intervention outweighed the undesirable effects) or conditional (the panel 
considered that the desirable effects of the intervention probably outweighed the 
undesirable effects). The certainty of evidence supporting each recommendation 
was graded as high, moderate, low or very low. Recommendations were then 
formulated by members of the Guidelines Development Group through discussions 
based on the certainty of the evidence, the balance of benefits and harms, 
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considerations of values and preferences, resource use and the feasibility of 
carrying out the intervention (72). The Chairs and methodologist worked to reach 
consensus during the meeting. After addressing all comments and questions from 
members of the Group, the Chair asked Group members whether they agreed with 
the recommendations to document consensus. All Group members agreed with all 
the recommendations. Implementation needs were subsequently evaluated, and 
areas and topics requiring further research identified. 
The draft guidelines was reviewed by the Guidelines Development Group and an 
external review group.
3.3 Roles
The Guidelines Development Group formulated the questions on population, 
intervention, comparison, outcomes (PICO), reviewed the evidence profiles 
and decision-making tables, composed and agreed upon the wording of the 
recommendations, and reviewed drafts of the guidelines document.
The guidelines methodologist ensured that the GRADE framework was 
appropriately applied throughout the guidelines development process. This 
included formulation of the PICO questions, ensuring the comprehensiveness 
and quality of the systematic reviews, and preparation of evidence profiles 
and decision-making tables. The methodologist also provided guidance to 
the Guidelines Development Group in formulating the wording and strength of 
the recommendations.
The External Review Group reviewed the draft guidelines document and provided 
critical feedback.
3.4 Declarations of interest and management of 
conflicts of interest
In accordance with WHO policy, all external contributors to the guidelines, including 
members of the Guidelines Development Group and the External Review Group, 
completed a WHO declaration of interest form (see Annexes 1 and 2, pages 80 
and 83). A brief biography of each member of the Guidelines Development Group 
was posted on the web. The biographies of the Group members are available 
on http://www.who.int/hepatitis/news-events/gdg-hepatitis-c/en/. The Steering 
Committee reviewed and assessed the declarations submitted by each member 
and agreed on an approach to assess potential conflicts of interest, which they 
discussed with a staff member of the WHO Compliance and Risk Management 
and Ethics Department. At the meeting, declarations of interest were reported 
according to WHO standard requirements. 
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Individuals from organizations that had received significant funding from private 
(primarily pharmaceutical) companies and individual researchers or clinicians 
who had received honoraria above US$ 5000 from pharmaceutical companies 
were considered to have a conflict of interest, and their participation in the 
Guidelines Development Group was classified as restricted. The Group members 
whose participation was restricted were Charles Gore, Francesco Negro, Jurgen 
Rockstroh and Alexander Thompson. These individuals contributed to the 
development of the PICO questions and provided technical expertise in reviewing 
the evidence summaries but were excluded from participation in the discussion, 
voting and formulation of the recommendations (see Annex 1, page 80).
The declarations of interest forms from members of the External Review Group 
were reviewed in accordance with the WHO guidelines development policy. 
Any conflicts of interest identified were considered when interpreting comments 
from External Review Group members during the external review process. The 
external reviewers could not and did not make changes in the recommendations 
(see Annex 2, page 83).
3.5 Dissemination and updating of the guidelines
The Global Hepatitis Programme Secretariat will disseminate the guidelines 
through WHO regional offices to WHO country offices and Ministries of Health, 
as well as to key international, regional and national collaborating centres, civil 
society organizations and national programmes. In addition, the guidelines will 
be made accessible on the WHO website with links to other United Nations and 
related websites.
The successful implementation of the recommendations in these guidelines will 
depend on a well-planned and appropriate process of adaptation and integration 
into relevant regional and national strategies. It is a process that will be determined 
by available resources, existing enabling policies and practices, and levels 
of support from partner agencies, nongovernmental organizations (NGOs) and 
civil society. 
Implementation of these guidelines can be measured by the number of countries 
that incorporate them into their national treatment programmes and actual 
treatment onset rates in countries, which is part of the cascade of care. With 
respect to policy uptake, the Global Hepatitis Programme (GHP) conducted a 
country profile survey in 2016/2017. With respect to the cascade of care, GHP has 
set up a monitoring and evaluation framework (73) and led a process to generate 
initial estimates for 2015 (9) and 2016 (4). In 2018, GHP will be setting up a 
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new system of routine reporting to obtain yearly updates on these two levels of 
indicators. This new system will be instrumental in measuring how much these 
guidelines are resulting in impact at country level.
The Guidelines Development Group recognized that the field of hepatitis treatment 
is evolving rapidly. New data are expected for the treatment of HCV-infected 
adolescents and children in the coming year; therefore, it is anticipated that an 
update will be needed in 2020.
3.6 Evidence that informed the recommendations
Systematic reviews, meta-analyses, modelling, cost–effectiveness analyses, values 
and preferences and a feasibility survey were undertaken to support the process 
of formulating recommendations and identifying patient-important outcomes. 
Existing national and international guidelines were also evaluated. 
3.6.1 Systematic reviews and meta-analyses
For the recommendation to Treat All persons diagnosed with HCV infection, WHO 
commissioned a systematic review and meta-analyses of morbidity and mortality 
from extrahepatic manifestations in persons with HCV infection (74). 
For the updated recommendations on treatment with DAAs, a systematic review 
was conducted. The manufacturers of the DAAs of interest (AbbVie and Gilead) 
were contacted to provide any additional data from clinical trials. To complement 
evidence from clinical trials, observational cohort studies that followed individuals 
receiving DAA treatment were taken into account. In addition, Médecins Sans 
Frontières (MSF) contributed data from their treatment programmes in South 
Africa and Cambodia. Search strategies and summaries of evidence are available 
in Web annexes 2, 3.1 and 3.2.
The decision-making table to inform treatment decisions of HCV-infected 
adolescents and children under the age of 18 years is available in Web annex 6.
3.6.2 Modelling
Modelling was carried out to predict the expected impact of HCV treatment on 
the incidence of new HCV infections. Existing national and subnational models 
were used to estimate the prevention impact by treating a fixed number of HCV 
infections in various regions (see Web annex 4). 
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3.6.3 Feasibility survey
An online feasibility survey was conducted to assess programmatic and personal 
experiences of introducing a Treat All recommendation. The online survey was 
sent to members of the Guidelines Development Group, who distributed the 
survey within their networks. The survey was completed by 10 programme 
managers, 145 health-care providers and 112 people living with HCV infection. 
The questionnaire focused on experiences and the perceived challenges of a Treat 
All recommendation, as well as suggested solutions provided by the participants 
(see Web annex 7).
3.6.4 Cost–effectiveness analyses
WHO commissioned a systematic review of the cost–effectiveness literature to 
evaluate the cost–effectiveness and population health outcomes of a Treat All 
scenario compared to a more restricted set of access policies (75).
3.6.5 Values and preferences
To provide information on values and preferences, a stakeholder survey 
was conducted and the literature reviewed to determine which characteristics 
of a treatment regimen are important from the patient’s perspective (see 
Web annex 7). 
CHAPTER 4. RECOMMENDATIONS 
4.1 Treatment with direct-acting antiviral agents: when 
to start treatment
New recommendation
4.1.1 Summary of the evidence 
Treating HCV infection is beneficial for all HCV-infected persons 
DAAs have been on the market since 2013, which means that there are no trials 
available that compared persons with HCV infection treated early with those treated 
late in terms of clinical outcomes. The Guidelines Development Group therefore 
examined the evidence of the benefit of treating all persons with HCV infection, 
irrespective of the stage of liver disease.
Treatment with DAAs leads to high rates of SVR. Systematic reviews of the 
effectiveness of DAAs for the treatment of chronic HCV infection indicate that SVR 
rates generally exceed 90%, except for those with the most advanced stages of 
cirrhosis (76) and persons infected with HCV genotype 3.
SVR is associated with reduced mortality from liver diseases and reduced risk 
of progression to HCC. A 2017 systematic review and meta-analysis indicated 
that HCV-infected persons with SVR following treatment had an 87% reduction 
in liver-related mortality, an 80% reduction in the incidence of HCC, and a 75% 
reduction in all-cause mortality (77) compared to HCV-infected persons who did 
not reach SVR. Many of these studies used older interferon-based treatment. 
Studies that considered only DAAs also indicate a reduction in mortality from liver 
diseases and HCC (78). DAAs would have a larger impact than interferon-based 
treatment overall because of a higher SVR rate. 
1 With the exception of pregnant women 
WHO recommends offering treatment to all individuals diagnosed with HCV infection 
who are 12 years of age or older,1 irrespective of disease stage. (Strong recommendation, 
moderate quality of evidence) 
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SVR is associated with improvement of extrahepatic manifestations. A 
systematic review and meta-analysis concluded that SVR reduced extrahepatic 
mortality (pooled odds ratio [OR]: 0.44, 95% confidence interval [CI]: 0.3–0.7). 
SVR was also associated with better outcomes related to cryoglobulinaemia 
(pooled OR: 21, 95% CI: 6.7–64.1) and lymphoproliferative diseases (pooled OR: 
6.5, 95% CI: 2–20.9), and decreased risk of major cardiovascular adverse events 
(pooled OR: 0.37, 95% CI: 0.2–0.6), incidence of de novo type 2 diabetes (pooled 
OR: 0.27, 95% CI: 0.2–0.4), depression (pooled OR: 0.59, 95% CI: 0.1–3.1), 
arthralgia (pooled OR: 0.86, 95% CI: 0.5–1.5) and fatigue (pooled OR: 0.52, 95% 
CI: 0.3–0.9) (74).
Treatment of adolescents is highly effective and well tolerated. Although 
advanced disease is uncommon among adolescents, a systematic review of two 
studies on the use of DAA regimens in adolescents >12 years of age indicated 
high SVR and excellent tolerance (see section 4.3). DAA treatment has also been 
reported to improve impaired cognitive functioning, educational attainment and 
well-being (79, 80). 
Treating all HCV-infected persons modestly reduces the risk of transmission. 
Globally, treating persons without any prioritization by risk or age group or by 
disease stage points to a modest effect of treatment as prevention. Modelling in 
82 countries distributed across all regions indicates that treating persons with HCV 
infection without any prioritization by risk or age group or by disease stage would 
prevent around 0.57 infections over 20 years for each person treated (see Web 
annex 4). However, this prevention benefit is highly variable across countries and 
WHO regions. Two main country-level factors influence the number of infections 
averted per person treated: the population growth rate, the HCV prevalence among 
PWID in their country (the contribution of injection drug use to the epidemic).
First, the number of infections averted per treatment increases with increasing 
population growth, suggesting that LMICs with higher population growth rates 
have the potential to achieve more prevention benefits through Treat All than high-
income countries.
Second, the number of infections averted per treatment decreases when injection 
drug use accounts for a substantial proportion of new infections, and the 
prevalence of HCV infection among PWID is high (prevalence >60%). In these 
epidemic scenarios, there are high rates of reinfection when PWID are treated 
while limited prevention benefit is achieved through treating other individuals 
who do not inject drugs. For treatment to achieve prevention benefits in these 
“concentrated epidemic” scenarios, HCV treatment needs to be given at higher 
rates (e.g. about 5% of infections need to be treated per year in Australia) and 
reinfection risks need to be reduced through scaling up comprehensive, effective 
harm reduction measures, such as needle and syringe programmes (NSPs) and 
OST (see Web annex 4). 
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4.1.2 Rationale for the recommendation
Balance of benefits versus harms of treating all HCV-infected persons
Benefits
Treatment of all patients has the potential to prevent more liver-related 
morbidity. A systematic review with meta-analysis and meta-regression estimated 
that the prevalence of cirrhosis at 20 years after the initial infection was 16% 
(14–19%) for all studies, ranging from 7% (4–12%) to 18% (16–21%) according 
to the types of studies and recruitment of individuals (15). Treating all persons 
diagnosed with HCV infection would prevent a large proportion of these avoidable 
complications. However, when expanding from treating persons with fibrosis to 
treating all HCV-infected persons, the additional gain in terms of years of life saved 
would occur further away in the future.
Extrahepatic manifestations are common and their occurrence is usually 
independent of liver fibrosis. Persons infected with HCV may suffer from 
comorbidities, including common extrahepatic manifestations (Fig. 2.2, Chapter 
2.1.1). 
Treatment of adolescents results in high SVR rates and is well tolerated. 
Early treatment also reduces the onset of cirrhosis and HCC (81–83), potentially 
reducing downstream costs of care (84, 85). Cure following DAA treatment may 
improve impaired cognitive functioning, educational attainment and well-being 
(79, 80). Cure enables adolescents to live free of a socially stigmatizing infection.
Treating all will facilitate a public health approach to implementation. 
Treating all persons diagnosed with HCV infection will simplify clinical decision-
making and patient management. Staging can be simplified and limited to the 
use of non-invasive methods to identify persons with cirrhosis. Most HCV-infected 
persons will be able to start treatment immediately, reducing the potential for loss 
to follow up that occurs when there are delays in starting treatment for HCV (86) 
as well as HIV disease (87). Simplifying disease stage assessment and laboratory 
investigations also facilitates treatment by non-specialized health-care workers, a 
critical strategy for providing treatment at scale (88–90). Task-sharing with non-
specialist providers has increased access to HIV testing and ART (91–93). 
Potential harms
Treating more HCV-infected persons could lead to more side-effects. DAAs 
have an excellent safety profile, particularly when compared with interferon therapy 
(76). In an approach where more apparently healthy persons will be treated with 
DAAs once prioritization for severity of liver disease is removed, the occurrence of 
rare side-effects that have not been identified during post-marketing surveillance 
is theoretically possible (94). However, such events are unlikely, given the clinical 
experience of using these medicines to date (76).  
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Treating hepatitis B virus (HBV)/HCV-coinfected persons can lead to HBV 
reactivation. Persons with HBV infection (hepatitis B surface antigen [HBsAg]-
positive) who are treated for HCV infection are at risk for reactivation of HBV infection 
(95). Persons who are HBsAg positive may need to be treated for HBV before they 
are treated for HCV (see section 5.2.2, Persons with HBV/HCV coinfection). The 
risk of reactivation among persons who are anti-hepatitis B core antibody (HBcAb) 
positive but HBsAg negative is very low (96). Deferring treatment of such persons 
because of concerns of HBV reactivation needs to be balanced against the risk of 
morbidity and mortality from untreated HCV infection. 
Treat All may lead to a perception that scaling up access to harm reduction is 
unnecessary. As treating all persons with HCV infection has an effect on incidence, 
there is a possibility that some stakeholders may underestimate the continued 
need for high-coverage harm reduction interventions for PWID. Harm reduction 
remains a critical component of the comprehensive package of interventions for 
PWID alongside treatment (see Web annex 4).
Values and preferences
Four studies were identified that assessed patient preferences related to HCV 
treatment (97–100). The most important patient-relevant outcome was overall 
treatment efficacy followed by risk of adverse events. Of 112 people living with HCV 
infection who responded to an online feasibility survey carried out by WHO, nearly 
all favoured a Treat All policy and advocated for universal access to treatment for 
all those with HCV infection (see Web annex 7). 
While there is clear support for a Treat All policy among people living with HCV 
infection, 18% of respondents expressed some concern about acceptability 
among HCV-infected persons without fibrosis or with mild fibrosis. This finding 
underscores the need for careful messaging to help HCV-infected persons 
understand the benefits of early treatment.
Health-care workers highly value cure for persons with HCV infection and 
expressed a preference for simplified patient management algorithms.
Programme managers understand that cure of more individuals through a Treat 
All policy will lead to progress towards elimination, and that simplifying the staging 
step with the use of serum biomarkers facilitates implementation and task-sharing 
(88–90, 101). Programme managers expressed a preference for strategies that 
represent cost-effective use of the resources available. Therefore, they would 
benefit from cost–effectiveness analyses that describe the relation between 
the cost incurred in the short term versus the savings in the future because of 
prevented sequelae of HCV infection and onward transmission (102, 103). 
19
Feasibility and acceptability
An online feasibility survey among 145 health-care providers indicated that 45% 
of respondents already had a Treat All policy at their place of work. Nearly all 
perceived it as feasible and desirable (see Web annex 7). 
Experience from HIV suggests that widening treatment access is feasible. In 
September 2015, WHO released guidance recommending Treat All for HIV-positive 
individuals (8). By the end of 2017, more than 70% of LMICs and almost all HICs 
had adopted the Treat All policy, demonstrating a high level of acceptability of this 
recommendation by policy-makers (104). Despite initial concerns about health 
system capacity to meet the demands of a Treat All approach, no major increase 
in medication stock-outs or other essential supplies have been reported during 
this period.
Equity and human rights
Therapeutic guidelines that restrict an individual’s access to HCV treatment when 
cure rates are high and adverse events are rare raise ethical challenges (105). 
Many HCV-infected persons from groups that are marginalized or stigmatized 
such as PWID, MSM, prisoners or migrants have poor access to health care. 
Progress towards a Treat All approach with equity in access regardless of age, risk 
group or stage of disease would help overcome some of the obstacles to access 
among these populations. Concerns that mandatory or coercive approaches might 
be used among highly affected marginalized populations highlight the importance 
of adequate information, informed consent, appropriate health worker training and 
rights-based legal frameworks to facilitate access. 
Resource considerations 
DAAs are cost effective or cost-saving. In general, in many countries, DAAs 
are cost effective or cost-saving for the large majority of subgroups (defined in 
terms of prior treatment experience, fibrosis stage and HCV genotype). Most 
published cost–effectiveness analyses do not include HCV transmission or the risk 
of reinfection. This omission may result in underestimating or overestimating the 
benefits of treatment (75).
Expanding treatment to the general population is cost effective. When 
applying country-specific willingness-to-pay thresholds, several studies from HICs 
and Egypt reported that expanding treatment in the general population is cost 
effective, though it may require substantial short-term payments to cover the cost 
of treatment. The cost–effectiveness of treatment expansion for individuals above 
65 years of age with mild fibrosis is highly sensitive to treatment price and, in some 
settings, where prices remain relatively high, may not be cost effective (75).
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Treating PWID along with provision of harm reduction interventions is cost 
effective. It is generally cost effective to treat HCV-infected PWID, but cost–
effectiveness is influenced by the potential for preventing new infections and by 
the risk of reinfection. Some studies also estimate that intensified case-finding in 
this group is cost effective along with treatment scale up, that treatment of all PWID 
was cost effective compared to delaying treatment until progression to a later stage 
of fibrosis, and that treatment can be cost effective even in a declining epidemic. 
However, in settings with a high burden of HCV infection among PWID, the cost–
effectiveness of preventing onward transmission via treatment is diminished by 
the high probability of reinfection in case of inadequate access to harm reduction 
programmes. This underscores the need for concurrent, high-coverage HCV 
prevention interventions with highly effective and cost-effective harm reduction 
programmes (75). 
Treating incarcerated individuals is cost effective. Studies from the United 
States of America (USA), Australia and the United Kingdom (UK) reported that it is 
generally cost effective to treat incarcerated individuals who are HCV infected (3). 
Testing upon entry to prisons can be cost effective if there is linkage to treatment 
that can be completed in prison or after release through continuity of care. Similar 
to the findings in PWID communities, concurrent investments in HCV prevention 
programmes complement investments in HCV treatment and make HCV treatment 
more cost effective by reducing the probability of reinfection (75). 
Budget implications. While DAAs are cost effective and/or cost-saving for the 
treatment of HCV infection, the short-term budget implications will depend on (i) 
the price of the medications and (ii) the size of the population to be treated (the 
latter being also affected by testing and linkage activities in the population). On the 
one hand, treating all will increase the budget impact. On the other hand, the Treat 
All policy should lead to price reductions as it will increase the volume of medicines 
purchased (see section 6.7 on Strategies for more efficient procurement and 
supply management of medicines and diagnostics and Table 6.2). To finance the 
treatment of all persons with HCV through a universal health coverage approach, 
a two-step approach is proposed.
•  Improving efficiencies and reducing costs. This can be done through 
the choice of high-impact interventions, simplified management and price 
reduction strategies for key commodities, including medicines, and improved 
service delivery, as has been demonstrated for other infectious diseases (106). 
The calculation for cost–effectiveness may be used to back-calculate the 
pricing level that DAAs should reach to be cost effective or cost-saving within 
a horizon that has been defined by those that finance the health sector (e.g. 
health insurance, national social security scheme, Ministry of Health); see the 
hepatitis C calculator (http://www.hepccalculator.org/). 
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•  Identifying innovative financing solutions. This can be done through both 
external and domestic funding, and innovative and fair budget allocation (107). 
4.1.3 Implementation considerations
•  Transitioning from a clinical prioritization approach to a Treat All approach 
requires planning with respect to the eight good principles of health-care 
service delivery (see Chapter 6 for service delivery models (88–90). 
•  The implementation and budget impact of a recommendation to treat all 
persons diagnosed with HCV infection need to be considered in the context of 
testing activities that identify more individuals to be treated.
•  If the budget impact of immediately implementing a Treat All recommendation 
is not affordable in the short term, national programmes may consider allocating 
resources preferentially to individuals at higher risk of hepatic and extrahepatic 
morbidity and mortality. 
•  Treatment of PWID needs to be integrated with harm reduction services to 
prevent reinfections, particularly in settings where the prevalence of HCV 
infection exceeds 60% in PWID.
•  Persons with HBV infection (HBsAg positive) may need to be treated for HBV 
before they are treated for HCV.
4.1.4 Research gaps
•  Long-term clinical studies of persons with early-stage HCV treated with DAAs.
•  Post-marketing surveillance for adverse events and drug resistance with 
expansion of antiviral treatment.
•  Cost–effectiveness and budget impact studies in a variety of settings.
•  Monitoring the impact of expansion of DAA treatment on the incidence of HCV 
infection, especially in populations such as PWID and MSM.
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4.2 Treatment of adults with direct-acting antiviral 
agents: what treatment to use
New recommendation
4.2.1 Summary of the evidence
TABLE 4.1 Currently available pangenotypic DAAs for the treatment of  
HCV-infected persons without cirrhosis
Evidence that pangenotypic DAAs are effective in HCV infection
A WHO-commissioned systematic review identified 142 clinical studies that 
evaluated the safety and efficacy of various FDA- and EMA-approved DAA 
regimens. These included sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, 
sofosbuvir/daclatasvir, daclatasvir/asunaprevir, elbasvir/grazoprevir, ledipasvir/
sofosbuvir, paritaprevir/ritonavir/ombitasvir/dasabuvir, sofosbuvir/velpatasvir/
voxilaprevir, sofosbuvir/daclatasvir/ribavirin, sofosbuvir/ribavirin. The complete 
evidence summaries for each of the regimens can be found in Web annex 3.1, 3.2 
and 8, with a short summary below.
Pangenotypic DAAs in HCV-infected adults without cirrhosis 
Sofosbuvir/velpatasvir
In combined treatment-naive and treatment-experienced persons treated with 
sofosbuvir/velpatasvir, the pooled SVR rates exceeded 96% (92–100%) for all 
six major genotypes, except for genotype 3 (SVR rate: 89%, 85–93%) (see Web 
annex 8 Table 4, page 17).
1 Pangenotypic is defined as an SVR rate >85% across all six major HCV genotypes
1  Persons with HCV genotype 3 infection who have received interferon and/or ribavirin in the past should be treated for 
16 weeks.
WHO recommends the use of pangenotypic DAA regimens for the treatment of persons 
with chronic HCV infection aged 18 years and above1 (Conditional recommendation,  
moderate quality of evidence).
HCV-infected persons without cirrhosis
glecaprevir/
pibrentasvir 
sofosbuvir/
daclatasvir
sofosbuvir/
velpatasvir
8 weeks1 12 weeks 12 weeks
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Glecaprevir/pibrentasvir
In combined treatment-naive and treatment-experienced persons treated with 
glecaprevir/pibrentasvir, pooled SVR rates exceeded 94% (89–100%) for infections 
with all six major genotypes. For the relatively rare genotype 5, two persons treated 
reached SVR (see Web annex 8 Table 2, page 4). 
Sofosbuvir/daclatasvir 
In combined treatment-naive and treatment-experienced persons treated 
with sofosbuvir/daclatasvir, the pooled SVR rates exceeded 92% for infection 
with genotypes 1, 2, 3 and 4. Data from an observational study (manuscript 
in preparation, MSF demonstration project) provided information on the less 
commonly reported genotypes 5 and 6. A total of eight persons with genotype 5 
and 123 persons with genotype 6 infection were treated with sofosbuvir/daclatasvir 
for 12 weeks. SVR rates were, respectively, 88% and 94% for genotypes 5 and 6 
(see Web annex 8 Table 3, page 10).
Pangenotypic DAAs in HCV-infected adults with compensated cirrhosis 
TABLE 4.2 Current available pangenotypic DAAs for the treatment of HCV- 
infected persons with compensated cirrhosis
Sofosbuvir/velpatasvir
In combined treatment-naive and treatment-experienced persons with cirrhosis 
treated with sofosbuvir/velpatasvir for 12 weeks, the pooled SVR rates in those 
infected with genotypes 1, 2 and 4 were 90%, 86% and 88%, respectively. The 
pooled SVR rate in genotype 3 infection was 97% in treatment-naive persons and 
90% in treatment-experienced persons. An additional study (published after the 
systematic review inclusion period ended) (108) reported SVR rates of 100% for 
both genotype 5 (N= 13) and genotype 6 (N = 20) after 12 weeks of treatment 
(see Web annex 3.1 Tables 40–42, page 46). 
1  Persons with HCV genotype 3 infection who have received interferon and/or ribavirin in the past should be treated for 
16 weeks.
2  In a population of persons with cirrhosis where 5% of persons would be infected with genotype 3 HCV, the SVR would 
be 80% in the 5% infected with genotype 3 and 93% in the 95% infected with other genotypes, leading to an overall 
SVR rate of (0.05x0.80)+(0.93x0.95) = 92%.
HCV-infected persons with compensated cirrhosis
glecaprevir/
pibrentasvir 
sofosbuvir/
daclatasvir
sofosbuvir/
daclatasvir
sofosbuvir/
velpatasvir
12 weeks1 24 weeks 12 weeks may be considered  
in countries where genotype  
3 distribution is known and 
prevalence is <5%2
12 weeks
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Glecaprevir/pibrentasvir
In combined treatment-naive and treatment-experienced persons with 
compensated cirrhosis treated with glecaprevir/pibrentasvir for 12 weeks, SVR 
rates exceeded 94% for infection with genotypes 1, 2, 3, 4 and 6. Two persons 
treated for infection with genotype 5 reached SVR (see Web annex 3.1 Table 35, 
page 43). 
Sofosbuvir/daclatasvir 
In combined treatment-naive and treatment-experienced persons with 
compensated cirrhosis treated with sofosbuvir/daclatasvir for 12 weeks, the pooled 
SVR rates exceeded 93% for infection with genotypes 1 and 2. SVR rates for 
infection with genotype 3 were low, ranging from 79% to 82%. However, after 24 
weeks of treatment , SVR rates increased to 90%. Data from an observational study 
(manuscript in preparation, MSF demonstration project) provided information 
on genotypes 5 and 6, and real-world data from Egypt provided information on 
genotype 4 (101). One cirrhotic person with genotype 5 infection treated with 
sofosbuvir/daclatasvir for 12 weeks reached SVR. Among 185 cirrhotic persons 
with genotype 6 infection treated with sofosbuvir/daclatasvir for 12 weeks, 92% 
reached SVR. Cirrhotic persons with genotype 4 infection had SVR rates that 
exceeded 98% after 12 weeks of treatment (101) (see Web annex 3.1 Tables 
29–31, page 39).
Safety of pangenotypic DAAs 
Treatment discontinuation due to adverse events was very low in persons without 
and with cirrhosis in the regimens discussed above (<1%). Similar results were 
observed in treatment-naive and treatment-experienced persons (see Web annex 
3.1 Tables 58–60, page 58).
4.2.2 Rationale for the recommendation
The Guidelines Development Group made an overall conditional recommendation 
to use pangenotypic DAA regimens for the treatment of HCV infection. The Group 
acknowledged that the potential clinical benefits of pangenotypic regimens are 
similar to those of non-pangenotypic regimens. However, pangenotypic DAAs 
present an opportunity to simplify the care pathway by removing the need for 
expensive genotyping and so simplifying procurement and supply chains. These 
regimens offer a major opportunity to facilitate treatment expansion worldwide. 
These factors shift the balance of benefits and harms in favour of the use of 
pangenotypic regimens, leading to a conditional recommendation. 
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The Guidelines Development Group acknowledged that there are countries where 
pangenotypic formulations may not yet be approved or available. In addition, there 
are countries where the HCV epidemic is almost entirely caused by one genotype, 
and where national hepatitis programmes successfully use a non-pangenotypic 
DAA regimen such as sofosbuvir/ledipasvir. In these cases and when treating 
adolescents, there remains a role for non-pangenotypic DAAs while national 
programmes transition to using pangenotypic regimens. Consequently, non-
pangenotypic DAAs listed in Web annex 5 may be used during a transition phase. 
Balance of benefits and harms
The use of pangenotypic regimens removes the need for genotyping. This 
simplifies medicine procurement and supply chains, may reduce costs and loss 
to follow up after diagnosis. Potential harms include the development of rare long-
term side-effects of these recently approved medicines, which may not have been 
identified during post-marketing surveillance, and the potential overtreatment of 
persons treated with sofosbuvir/daclatasvir if persons are treated for 24 weeks in 
the absence of genotyping.
Values and preferences and acceptability
Four identified studies investigated the preferences of HCV-infected persons 
regarding HCV treatment regimens. For persons infected with HCV, the likelihood 
of a cure and the lack of adverse events are the most important considerations 
related to treatment regimens, though factors such as a shorter (e.g. 8-week) 
course of treatment were also valued (97–100). Therefore, use of pangenotypic 
regimens would be acceptable. 
Resource considerations
The resources required to administer HCV therapy can be broadly divided into 
health system costs (e.g. laboratory and personnel) and the price of medicines. 
Treating persons with pangenotypic DAAs incurs fewer health system costs as 
it removes expensive genotyping, which requires specialist laboratories and 
personnel, saving up to US$ 200 per test in LMICs. The Guidelines Development 
Group recognizes, however, that access to pangenotypic DAA regimens remains 
limited in many LMICs (see Chapter 6, Table 6.2). Prices for sofosbuvir/velpatasvir 
and glecaprevir/pibrentasvir are still higher than the older DAA combinations, but 
it is expected that prices will substantially decrease as the volume of use increases 
and access policies for HCV-infected persons living in LMICs are optimized. 
Feasibility
The WHO progress report on access to hepatitis C treatment points to the feasibility 
of widening access to HCV treatment with the use of pangenotypic DAAs (4). 
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Equity
Simplifying the care pathway by using pangenotypic regimens could improve 
equity and help improve access to populations that currently do not have access 
to HCV treatment.
4.2.3 Implementation considerations
Countries need to plan for transitioning to the use of pangenotypic DAA regimens. 
The speed of transition may depend on the prevalence of HCV infection, the 
distribution of HCV genotypes and how effective their current DAA regimens are 
in treating infection with these genotypes. (For key steps to implementation, see 
section 6.7.) 
4.2.4 Research gaps
•  More data on the efficacy and safety of pangenotypic regimens are required in 
specific subpopulations, including those with severe renal impairment, persons 
under the age of 18 years and pregnant women.
•  Predictive factors for selecting persons who could be treated for a shorter 
duration.
•  Data on the cost–effectiveness of pangenotypic DAAs in LMICs. 
•  The clinical importance of NS5A resistance.
•  Data on treatment failure and the relation with rare HCV genotypes.
4.3 Treatment of adolescents (12–17 years) and 
deferral of treatment in children (<12 years of age)
New recommendation
What treatment to use 
In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV,* WHO 
recommends:
•  sofosbuvir/ledipasvir for 12 weeks** in genotypes 1, 4, 5 and 6  
(strong recommendation, very low quality of evidence)
• sofosbuvir/ribavirin for 12 weeks in genotype 2 (strong recommendation, very low 
quality of evidence)
•  sofosbuvir/ribavirin for 24 weeks in genotype 3 (strong recommendation, very low 
quality of evidence).
* In those without cirrhosis or with only compensated cirrhosis  
** Treatment for 24 weeks in those who are treatment experienced and with compensated cirrhosis
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4.3.1 Background 
To date, the global response to the HCV epidemic focused on the adult HCV-infected 
population. Compared with adults, there are major gaps in data and evidence to 
inform management practices and policies in adolescents and children. 
Prior to regulatory approval of DAA’s for use in children, the standard of care of 
adolescents and children infected with HCV was dual therapy with pegylated-
interferon and ribavirin for 24 weeks for genotypes 2 and 3, and 48 weeks for 
genotypes 1 and 4 (109–117). This combination resulted in an SVR rate of around 
52% in children infected with HCV genotypes 1 and 4, and 89% in those infected 
with HCV genotypes 2 and 3 (109, 110, 112, 114), but was associated with 
significant side-effects. 
In 2017, two DAA regimens (sofosbuvir/ledipasvir and sofobuvir/ribavirin) received 
regulatory approval from FDA and EMA for use in adolescents (≥12 years) 
(118, 119). Trials are ongoing to evaluate pangenotypic DAA regimens in both 
adolescents (≥12 years) and children (aged 6–11 years). As of June 2018, in 
those younger than 12 years, the only licensed treatment options remain interferon 
with ribavirin as DAAs are not yet approved for use in younger children, and the 
Guidelines Development Group therefore formulated separate recommendations 
for adolescents and children. None of the recommended pangenotypic DAAs in 
these current guidelines (sofosbuvir/daclatasvir or sofosbuvir/velpatasvir) are yet 
approved for use in either adolescents and children, but this is anticipated in 
2019, which would represent a major opportunity to advance treatment access 
(120, 121). 
In children aged less than 12 years with chronic hepatitis C,* WHO recommends:
•  deferring treatment until 12 years of age** (conditional recommendation, low quality  
of evidence) 
•  treatment with interferon-based regimens should no longer be used*  
(strong recommendation, very low quality of evidence).
* In those without cirrhosis or with only compensated cirrhosis  
**Prior to approval of DAAs for children aged <12 years of age, exceptional treatment with interferon + ribavirin may be 
considered for children with genotype 2 or 3 infection and severe liver disease. This may include children at higher risk 
of progressive disease, such as with HIV coinfection, thalassaemia major and survivors of childhood cancer. 
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4.3.2 Summary of the evidence
The main evidence base to support treatment recommendations in adolescents 
aged 12 or more years were the two studies used for regulatory approval of the 
regimens (118, 119), and the extensive evidence base from DAA trials in adults. 
Adolescents (12–17 years)
The regulatory approval by the FDA and EMA in April and June 2017, respectively, 
of the use of a fixed-dose combination of sofosbuvir/ledipasvir for genotype 
1-infected adolescents aged 12–17 years old or weighing  ≥35 kg, and sofosbuvir/
ribavirin for those infected with HCV genotype 2 or 3 was based on the extensive 
data in adults of high rates of cure and low rates of toxicity, and two studies of 
pharmacokinetics, efficacy and safety in adolescents (118, 119). In one study, 
100 genotype 1 HCV-infected treatment-naive and -experienced adolescents were 
treated with sofosbuvir/ledispasvir as a single tablet once daily for 12 weeks (118). 
The SVR was 98% with good tolerability. A second study evaluated the use of 
sofosbuvir and weight-based ribavirin for 12 weeks in 52 adolescents with genotype 
2 or 3 infection (119). SVR rates were 100% (13/13) in genotype 2 and 97% 
(38/39) in persons with genotype 3. No serious adverse effects leading to treatment 
discontinuation or significant abnormalities in laboratory results were reported. This 
study also reported an improvement in health-related quality of life following SVR 
(122), particularly in social functioning and school performance domains. 
Children (6–12 years) 
Currently, the only licensed, approved treatment option for children younger than 
12 years is pegylated-interferon α-2a or -2b injections with twice-daily ribavirin 
tablets, for 24 to 48 weeks depending on the HCV genotype (109–117). In 
genotype 1, the SVR of pegylated-interferon/ribavirin is suboptimal compared to 
DAAs; and only 52% in those with HCV genotype 1 and 4, but 89% in genotypes 
2 and 3 (109–111, 114). Pegylated-interferon and ribavirin are associated with 
significant side-effects, and potentially irreversible post-therapy side-effects, such 
as thyroid disease, type 1 diabetes, ophthalmological complications and growth 
impairment (112, 114, 123–127). None of the DAAs are approved yet for use 
in children aged less than 12 years. There are two ongoing studies of half-dose 
sofosbuvir/ledipasvir in 90 treatment-naive or -experienced children aged 6 to 12 
years infected with HCV genotypes 1, 3 and 4, and sofosbuvir plus ribavirin in 
children aged 6 to 12 years (120).
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4.3.3 Rationale for the recommendations
Balance of benefits and harms 
Among the Guidelines Development Group there was consensus that the overall 
goal of treatment in adolescence and childhood is to prevent HCV-associated liver 
damage and extrahepatic manifestations, together with the potential to achieve an 
HCV-free generation through earlier treatment. 
Treat adolescents ≥12 years or weighing at least 35 kg (without cirrhosis or 
with only compensated cirrhosis) with sofosbuvir/ledipasvir and sofosbuvir/ribavirin 
The Guidelines Development Group recommended that all chronically HCV 
infected adolescents should be offered treatment with the current FDA- and EMA-
approved regimens of sofosbuvir/ledipasvir and sofosbuvir/ribavirin. Data on DAA 
therapy in HCV-infected adolescents is limited. The recommendation was based 
on both indirect evidence from adult treatment studies (discussed in Chapter 4.2, 
see Web annexes 3.1 and 3.2) and two published trials in adolescents (118, 119) 
of specific recommended regimens (sofosbuvir/ledipasvir and sofosbuvir/ribavirin) 
used for regulatory approval by the EMA and FDA that showed high efficacy and 
safety rates and pharmacokinetic equivalence. A systematic review and meta-
analysis comparing DAAs with pegylated-interferon in adolescents (128) also 
confirmed higher efficacy and tolerability of oral short-course DAA treatments when 
compared to interferon therapy in adolescents and children.This recommendation 
was therefore strong despite the low quality of evidence specific to adolescents. 
The Guidelines Development Group recognized that the recommended regimens 
had limitations. 
1.  These regimens are not pangenotypic and therefore genotyping will still be 
required. Pangenotypic DAA regimens would be preferable in settings with a 
range of genoptypes. DAAs under evaluation in adolescents include sofosbuvir/
velpatasvir, sofosbuvir/daclatasvir and glecaprevir/pibrentasvir.
2.  There remains limited data on treatment in those with cirrhosis, but 
recommendations include those with compensated cirrhosis. In those who are 
treatment experienced and with compensated cirrhosis, treatment for 24 weeks 
is recommended.
3.  Use of a ribavirin-based regimen requires haematological monitoring. Ribavirin 
is also teratogenic and contraindicated in pregnancy. This is important as 
adolescents are more likely to have unplanned pregnancies. Extreme care 
must be taken to avoid pregnancy during therapy and for 6 months after 
completion of therapy, as well as in partners of HCV-infected men who are 
taking ribavirin therapy.
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4.  Sofosbuvir with ribavirin is a suboptimal regimen for persons with genotype 3 
infection, especially if they have cirrhosis. The Guidelines Development Group 
noted that the EMA indicates that sofosbuvir/ledipasvir can be considered for 
use in some persons infected with genotype 3, and so a potential off-label use 
of sofosbuvir/ledipasvir plus ribavirin is a possible option for adolescents with 
genotype 3 HCV infection.
Deferral of treatment in children until 12 years 
In children less than 12 years, the Guidelines Development Group recommended 
that treatment be deferred until they either reach 12 years or until DAA regimens 
are approved for those less than 12 years. Interferon-based regimens should 
no longer be used for either adolescents or children (except in situations where 
there is no alternative). The Guidelines Development Group recognized that the 
benefits of deferral far outweigh the small risk of progression of liver fibrosis during 
childhood, and the unpredictable rapid development of advanced liver disease in 
a few children (83, 129).
The key reasons for the current conditional recommendation to defer HCV 
treatment in children aged less than 12 years were as follows:
1.  The low frequency of HCV-related liver disease in childhood. Only a small 
number of children experience significant morbidity that would benefit from 
early treatment.
2.  The only available and approved regimen for this age group is pegylated-
interferon/ribavirin. This regimen has an overall low efficacy, a prolonged 
treatment duration (6–12 months), an inconvenient administration route (via 
injection), significant side-effects and high costs. 
3.  New, highly effective short-course oral pangenotypic DAA regimens are likely to 
become available for children <12 years in 2019.
Treatment with interferon should not be used
The key reasons for the current strong recommendation that interferon should 
not be used in children aged less than 12 years despite the very low quality of 
evidence were as follows:
1.  The issues with interferon-containing regimens and ribavirin in children. 
These include long duration of treatment, limited efficacy and burdensome 
side-effects, including high rates of flu-like symptoms and haematological 
complications (anaemia, leukopenia and neutropenia), and several 
potentially irreversible side-effects, such as thyroid disease, type 1 diabetes, 
ophthalmological complications and impaired growth (112, 114, 123–127).
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2.  The imminent arrival of alternative DAA options. Preliminary trial data 
show much higher efficacy and safety of DAAs in children less than 12 years 
compared to interferon, as observed for adults and adolescents. 
3.  The low availability of interferon. Interferon is increasingly less available, 
especially in LMICs. It requires a cold chain, which makes delivery to scale 
less feasible. 
Values and preferences and acceptability
Curative, short-course (e.g. 12-week) oral DAA treatment is highly acceptable 
to adolescents and children, as well as their parents or caregivers (80), because 
of the likelihood of a cure, and minimal side-effects compared to interferon 
injections. Cure will enable adolescents and children to live free of a socially 
stigmatizing infection. 
Resource considerations
Treatment of adolescents (and in the future children <12 years) may avoid the 
higher costs associated with treating adults with advanced liver disease and 
related complications. Deferring treatment until children reach 12 years and can 
be treated with DAAs (or until approval of DAAs in younger children), has the 
potential to reduce costs, as interferon is more expensive. 
Equity 
The approval of DAAs for use in adolescents is a major opportunity to advance 
treatment access and cure to a vulnerable group that will benefit from 
early treatment.
4.3.4 Implementation considerations
A major constraint to implementation of these recommendations is that few LMICs 
have included adolescents and children in their national testing and treatment 
guidelines, so most remain undiagnosed. All countries should include testing 
for adolescents and children, and treatment for adolescents in their national 
guidelines, based on the recommendations of the 2017 WHO testing guidelines 
(3). This includes focused testing of adolescents from populations most affected 
by HCV infection (e.g. PWID, MSM, HIV-infected persons, children of mothers 
with chronic HCV infection, especially if HIV-coinfected) and those with a clinical 
suspicion of viral hepatitis. The age of consent for testing varies across countries, 
and this can pose barriers to adolescents’ access to services. Engaging adolescents 
in testing and treatment should be based on adolescent-friendly services. 
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4.3.5 Research gaps 
•  Evaluation of short-course pangenotypic regimens in adolescents and children, 
and retreatment options for children who experience DAA failure.
•  Estimates of prevalence and burden in adolescents and children to 
inform needs.
•  Cohort studies to examine clinical outcomes of chronic HCV that is vertically 
acquired and in childhood to guide indications for treatment initiation in 
younger children. 
•  Follow-up studies to examine the impact of DAA treatment on growth, cognitive 
function, educational attainment and quality of life among children. 
 
CHAPTER 5. CLINICAL CONSIDERATIONS
The three considerations (boxes below) are existing formal WHO 
recommendations that address alcohol intake, fibrosis assessment and treatment 
response assessment.
All other considerations discussed in this chapter are based on good 
practice principles.
Existing recommendation from the 2016 HCV treatment guidelines (2)
An alcohol intake assessment is recommended for all persons with HCV infection followed 
by the offer of a behavioural alcohol reduction intervention for persons with moderate-to-high 
alcohol intake. (Strong recommendation, moderate quality of evidence)
Existing recommendation from the 2016 HCV treatment guidelines (2)
In resource-limited settings, it is suggested that aminotransferase/platelet ratio index (APRI) 
or FIB-4 be used for the assessment of hepatic fibrosis rather than other non-invasive tests 
that require more resources such as elastography or FibroTest.  
(Conditional recommendation, low quality of evidence)
Note: This recommendation was formulated assuming that liver biopsy was not a feasible option. FibroScan®, which is more 
accurate than APRI and FIB-4, may be preferable in settings where the equipment is available and the cost of the test is not a 
barrier to testing.
Existing recommendation from the 2017 hepatitis B and C testing guidelines (3)
Nucleic acid testing for qualitative or quantitative detection of HCV RNA should be used  
as test of cure at 12 or 24 weeks (i.e. sustained virological response [SVR12 or SVR24])  
after completion of antiviral treatment. (Conditional recommendation, moderate/low  
quality of evidence)
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5.1 Clinical assessment of persons with HCV infection 
prior to treatment 
Pretreatment evaluation of the risk of adverse events is based on the person’s 
clinical information, concomitant medications and knowledge of treatment regimen 
to be administered. Women of childbearing age may be offered pregnancy testing 
and are informed about the lack of available data on the safety and efficacy of 
DAAs during pregnancy. In addition, in 2016, WHO recommended an alcohol 
intake assessment before initiating treatment and a fibrosis assessment using 
noninvasive tests such as the APRI score or FIB-4 test (formula in Fig. 5.1) 
to determine if there is cirrhosis (2). An online calculator is available at http://
www.hepatitisc.uw.edu/page/clinical-calculators. Tables 5.1 and 5.2 summarize 
the cut-off values for the detection of significant fibrosis and cirrhosis, and the 
sensitivity and specificity of the APRI score and FIB-4 test when using these cut-
offs. This information will allow clinicians to decide on the appropriate treatment 
duration of the pangenotypic regimen of their choice based on the absence or 
presence of cirrhosis. The treatment duration of the recommended pangenotypic 
regimens sofosbuvir/daclatasvir and glecaprevir/pibrentasvir depends on the 
absence or presence of cirrhosis. 
APRI = [(AST (IU/L)/AST_ULN (IU/L))×100]/platelet count (109/L)
FIB-4= age (years) x AST (IU/L)/platelet count (109)/L x [ALT (IU/L)1/2]
FIG. 5.1 APRI and FIB-4 formulas
APRI: aminotransferase/platelet ratio index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IU: interna-
tional unit; ULN: upper limit of normal
TABLE 5.1 Low and high cut-off values for the detection of significant fibrosis and cirrhosis
APRI (low  
cut-off)
APRI (high  
cut-off)
FIB-4 (low 
cut-off)
FIB-4 (high 
cut-off)
Significant fibrosis 
(METAVIR ≥F2)
0.5 1.5 1.45 3.25
Cirrhosis
(METAVIR F4)
1.0 2.0 – –
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TABLE 5.2 Sensitivity and specificity of APRI and FIB-4 for the detection of advanced  
fibrosis and cirrhosis
APRI (low  
cut-off)
APRI (high  
cut-off)
FIB-4 (low  
cut-off)
FIB-4 (high 
cut-off)
Significant fibrosis 
(METAVIR ≥F2)
Sensitivity 
(95% CI)
82  
(77–86)
39
(32–47)
89 
(79–95)
59 
(43–73)
Sensitivity 
(95% CI)
57
(49–65)
92
(89–94)
42
(25–61)
74
(56–87)
Cirrhosis
(METAVIR F4)
Sensitivity 
(95% CI)
77
(73–81)
48
(41–56)
– –
Sensitivity 
(95% CI)
78
(74–81)
94
(91–95)
– –
5.1.1 Drug–drug interactions
Drug–drug interactions (DDIs) for DAA regimens vary both in number and clinical 
significance, depending on the medicines prescribed. Commonly prescribed 
medicines that may lead to DDIs include proton pump inhibitors, statins, 
antidepressants and antiretrovirals (ARVs) for HIV (now recommended for all 
HIV-infected persons, regardless of CD4 count) (130). The association between 
recommended pangenotypic regimens and efavirenz is either contraindicated (in 
the case of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) or requires dose 
adjustment (in the case of sofosbuvir/daclatasvir). Table 5.3 summarizes the DDIs 
between WHO-recommended HIV ARV medicines and HCV medicines. Where 
DDIs are likely, ARV substitutions may be considered before initiating HCV therapy. 
Prescribers may consult the University of Liverpool webpage on hepatitis drug 
interactions (http://www.hep-druginteractions.org/) prior to prescribing, as details 
of interactions are frequently updated. This website includes details of interactions 
with prescribed and non-prescribed medicines. 
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5.1.2 Monitoring for treatment toxicity 
In general, DAAs are well tolerated by persons with HCV infection, with only minor 
side-effects. The American Association for the Study of Liver Diseases (AASLD) 
and the European Association for the Study of the Liver (EASL) recommend a 
monitoring schedule that includes baseline, week 4 and week 12 after the end of 
treatment (131, 132). The Guidelines Development Group proposed to simplify 
this schedule as the most common adverse events of DAAs are minor and include 
fatigue, headache, insomnia and nausea. The Guidelines Development Group 
proposed that the frequency of routine laboratory monitoring be limited to a baseline 
and end-of-treatment specimen (see summary monitoring schedule framework for 
the treatment of persons with HCV infection based on expert opinion in Table 5.4).
Additional laboratory monitoring is necessary in persons treated with ribavirin. 
Ribavirin is taken with food and causes a predictable, dose-dependent haemolytic 
anaemia. It is contraindicated in persons with anaemia or those with blood disorders 
such as thalassaemia. Finally, HIV coinfection, HBV coinfection (see sections 5.2.1 
and 5.2.2), cirrhosis or renal impairment, potential DDIs and ill-health may also 
necessitate more frequent monitoring than proposed in Table 5.4. 
TABLE 5.3 Drug–drug interactions between antiretrovirals and direct-acting antivirals
DAAs ABC ATZ/r DRV/r DTG EFV LPV/r NVP RAL TDF TAF ZDV XTC
Daclatasvir Adjust 
dose 
Adjust 
dose
Glecaprevir/ 
pibrentasvir
Sofosbuvir
Sofosbuvir/ 
ledipasvir
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor  
for renal 
toxicity  
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
when 
used 
with 
EFV or 
boosted 
protease 
inhibitor
Sofosbuvir/ 
velpatasvir
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
when 
used 
with 
TDF
Monitor 
for renal 
toxicity 
Red = do not co-administer
Yellow = possible toxicity/interaction/dose adjustment, as specified
Green = no interaction; can be co-administered 
ABC: abacavir; ATZ/r: atazanavir/ritonavir; DRV/r: darunavir/ritonavir; DTG: dolutegravir; EFV: efavirenz; LPV/r: lopinavir/r; 
NVP: nevirapine; RAL: raltegravir; ZDV: zidovudine; TDF: tenofovir disproxil fumarate; XTC: emtricitabine/lamivudine; 
TAF: tenofovir alafenamide
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a Recommended treatment for adolescents with genotypes 2 and 3 HCV infection 
b If Hb >10 g/dL then no need to check again at week 4
TABLE 5.4 Monitoring framework before and during DAA treatment
Time DAA alone DAA + ribavirina
Full blood count, renal,  
liver function 
Full blood count, renal,  
liver function 
Baseline Xb X
Week 4 X
Week 12 after end of treatment X X
5.1.3 Monitoring for treatment response
In 2017, WHO recommended that following completion of DAA treatment, 
SVR should be assessed at 12 weeks after the end of treatment using HCV 
RNA NAT (3). 
5.2 Clinical considerations for specific populations
5.2.1 Persons with HIV/HCV coinfection  
Persons with HIV/HCV coinfection generally have more rapid disease progression 
than monoinfected persons (133, 134). Even among persons in whom ART leads 
to successful control of HIV infection (i.e. undetectable HIV viral load), the risk of 
hepatic decompensation among coinfected persons is higher than among persons 
with HCV monoinfection (135, 136). For these reasons, since 2014, the WHO 
Guidelines listed persons with HIV/HCV coinfection among those to be prioritized 
for HCV treatment (1).
HCV treatment outcomes with DAAs are comparable in persons with HIV/HCV 
coinfection to those with HCV monoinfection (137). Because DAAs are safe and 
effective for people with HIV/HCV, there is no longer any need to consider them 
as a special or difficult-to-treat population. However, there are important DDIs 
with pangenotypic HCV regimens and ART. Therefore, checking for DDIs between 
HIV and HCV medications needs to be emphasized (see also section 5.1.1 
and Table 5.3). 
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5.2.2 Persons with HBV/HCV coinfection 
There are no global prevalence data on HBV/HCV coinfection, but various studies 
have reported that 3–18% of people who are HBsAg positive are also HCV infected 
(138). HBV/HCV coinfection is more likely among PWID and persons living in areas 
where both viruses are endemic (138). Coinfection with HBV and HCV increases 
the risk for HCC, although the reasons for this are not well understood (139, 140). 
In 2016, the FDA issued a warning about the risk of HBV reactivation during 
DAA treatment (defined as >1000 IU/mL increase in HBV DNA or detection of 
HBsAg in a person who was previously negative) based on 29 case reports (95). 
Even though HBV reactivation appears rare, individuals may be considered for 
HBV testing before initiating HCV treatment (131, 141). Persons with HBV/ HCV 
coinfection may be assessed for eligibility for HBV treatment and, if needed, 
started on HBV treatment before starting HCV treatment (131, 141). Persons with 
advanced disease may be considered for monitoring at regular intervals for HBV 
reactivation during HCV treatment. The risk of reactivation among persons who are 
anti-HBc positive but HBsAg negative is very low (142–144). 
5.2.3 Persons with cirrhosis
The risk of cirrhosis is increased in those who consume excess alcohol (145), and 
in those coinfected with HBV and/or HIV (133, 135, 136, 139), particularly those 
who are not receiving ART (146). To determine if fibrosis or cirrhosis is present, 
WHO recommends the use of non-invasive tests such as the APRI score or the 
FIB-4 test (see section 5.1) (2).
Management of compensated cirrhosis
Assessment and follow up for progression of disease and evidence of HCC is 
an essential part of the care of persons with HCV-related cirrhosis. Persons with 
cirrhosis (including those who have achieved SVR) may be considered for HCC 
screening with six-monthly ultrasound examinations and/or alpha-fetoprotein 
estimation (131, 141), and endoscopy every 1–2 years to exclude oesophageal 
varices (147). 
Management of decompensated cirrhosis
Diagnosis of decompensated liver disease is based on both laboratory and clinical 
assessment. A proportion of persons with decompensated liver disease will 
deteriorate on treatment and currently there are no predictors to identify these 
persons. Therefore, treatment of persons with decompensated cirrhosis ideally 
takes place in centres with the expertise to manage complications and where 
access to liver transplantation is available.
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Daclatasvir, velpatasvir and sofosbuvir have been studied in persons with 
decompensated cirrhosis and their use has been demonstrated to be generally 
safe and effective. In contrast, regimens that include an HCV protease inhibitor 
(e.g. glecaprevir/pibrentasvir) are not approved for use in persons with 
decompensated liver disease. 
5.2.4 Persons with chronic kidney disease
Glecaprevir/pibrentasvir have been shown to be effective and safe in persons with 
chronic kidney disease and HCV infection with all six major HCV genotypes (63). 
However, in 2018, there is limited availability in LMICs of this regimen, hence as 
an interim measure where genotype appropriate, consideration could be given to 
those combinations previously recommended in the WHO 2016 HCV treatment 
guidelines (2) and listed in Web annex 5 as safe in persons with grades 4 and 5 
chronic kidney disease. 
Sofosbuvir-based regimens do not have the safety and efficacy data to support 
their use in persons with chronic kidney failure grades 4 and 5, i.e. severe renal 
impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2).
5.2.5 Persons with TB/HCV coinfection
Persons at increased risk of infection with HCV may also be at increased risk of 
infection with TB. Therefore, the clinical evaluation of persons being considered 
for HCV treatment can include screening for active TB. A four-symptom screening 
algorithm exists to rule out active TB (148). If the person does not have any one 
of the following symptoms – current cough, fever, weight loss or night sweats – 
TB can be reasonably excluded; otherwise, the person must undergo further 
investigations for TB or other diseases.
Most of the DAAs interact with metabolic pathways in the liver, which increases or 
decreases the level of DAAs when co-administered with commonly used rifamycins 
such as rifabutin, rifampin and rifapentine (149–151). Therefore, concurrent 
treatment of HCV infection and TB must be avoided. Active TB involves a risk of 
secondary transmission and that can be life-threatening in a shorter time frame 
than HCV. Thus, TB is usually treated before HCV. In persons with HCV infection 
treated for TB, the risk of antimycobacterial-induced hepatotoxicity is higher than 
in those with TB monoinfection, although the risk of severe hepatotoxicity is rare 
(152). Monitoring liver function tests detects hepatotoxicity early.
Concurrent treatment of HCV infection and multidrug-resistant TB is particularly 
complicated because of many DDIs between DAAs and second-line antimicrobials. 
There are limited data on the management of persons coinfected with HCV, HIV 
and TB. Specialist referral may be needed to reduce the additive side-effects, pill 
burden and DDIs.
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5.2.6 Retreatment of persons with failure of DAA therapy
With DAAs, SVR rates generally exceed 90% across all HCV genotypes (76). Even 
if all of the 71 million persons with HCV infection were to gain access to DAA 
therapy, an estimated 2–5 million of them would not be expected to achieve SVR, 
and would need effective retreatment. Persons who do not achieve SVR after DAA 
treatment have limited options for retreatment. An appropriate, highly effective 
initial treatment regimen helps avoiding the dilemma of limited retreatment 
options. Examination of adherence and potential DDIs may guide decisions when 
persons fail DAA therapy.
Currently, there is one pangenotypic regimen approved for the retreatment of 
persons who have been previously treated with any combination of DAAs. This 
is the FDC of sofosbuvir, velpatasvir and the protease inhibitor voxilaprevir (153, 
154). In two clinical trials of sofosbuvir/velpatasvir/voxilaprevir, more than 300 
persons, 46% with cirrhosis, were treated for 12 weeks. The triple DAA regimen 
was highly effective for persons who did not reach an SVR with DAA-containing 
regimens. SVR rates ranged from 93% to 99%, with the lowest rate in persons 
with genotype 3 infection and cirrhosis (155). Sofosbuvir/velpatasvir/voxilaprevir 
cannot be used in persons with Child–Pugh Class B or C cirrhosis or renal failure. 
The combination of glecaprevir/pibrentasvir has been approved for retreatment 
in patients who have failed sofosbuvir-containing regimens and those who have 
failed treatment with either a protease inhibitor or an NS5A inhibitor (but not both). 
In the absence of these regimens, expert consultation suggests that extending 
the initial DAA therapy to 16 or 24 weeks, while at the same time reinforcing 
adherence, may be an alternative option for retreatment.
CHAPTER 6. SIMPLIFIED SERVICE  
DELIVERY FOR A PUBLIC HEALTH  
APPROACH TO TESTING, CARE AND 
TREATMENT FOR HCV INFECTION
Background
In 2016, WHO estimated that only 13% of persons diagnosed with HCV infection 
had initiated treatment (4). This chapter provides a summary of eight key 
good practice approaches to service delivery across the continuum of care to 
support implementation of the clinical recommendations for Treat All and use of 
pangenotypic regimens. These would help countries improve access to effective 
hepatitis services (Box 6.1).
Box 6.1. Good practice principles for health service delivery 
1.   Comprehensive national planning for the elimination of HCV infection based on local 
epidemiological context, existing health-care infrastructure, current coverage of testing, 
treatment and prevention, and available financial or human resources
2.  Simple and standardized algorithms across the continuum of care from testing, linkage  
to care and treatment
3. Strategies to strengthen linkage from testing to care, treatment and prevention
4.  Integration of hepatitis testing, care and treatment with other services (e.g. HIV  
services) to increase the efficiency and reach of hepatitis services 
5.   Decentralized testing and treatment services at primary health facilities or harm reduction 
sites to promote access to care. This is facilitated by two approaches: 
 5a.  task-sharing, supported by training and mentoring of health-care workers and  
peer workers;
 5b.  a differentiated care strategy to assess level-of-care needs, with specialist referral  
as appropriate for those with complex problems. 
6.  Community engagement and peer support to promote access to services and linkage  
to the continuum of care, which includes addressing stigma and discrimination 
7.  Strategies for more efficient procurement and supply management of quality-assured, 
affordable medicines and diagnostics 
8.  Data systems to monitor the quality of individual care and coverage at key steps along  
the continuum or cascade of care at the population level. 
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6.1 National planning for HCV elimination
In 2015, WHO published a manual to guide national programme managers in 
developing or strengthening national viral hepatitis plans (156). The manual is 
aligned with a health systems approach to disease planning and supports an 
evidence-based decision-making process. It includes a template for a national 
hepatitis plan that covers prevention, testing and treatment within the framework 
of universal health coverage principles and other planning tools. National 
stakeholders should also use the plan to agree on the service coverage targets for 
the interventions towards achievement of elimination.
6.2 Simple standardized algorithms 
A simplified algorithm is given for testing, treatment and monitoring with five key 
steps that can be adapted for use at the national level (see summary algorithm in 
the Executive summary).
6.3 Strategies to strengthen linkage from testing  
to care
Multiple factors may hinder successful uptake of testing and linkage to care, 
treatment and prevention. These include patient-level factors (e.g. mental health 
issues, substance abuse, misinformation, depression, lack of social or family 
support, fear of disclosure and housing instability), as well as structural or economic 
factors (e.g. stigma and discrimination, high cost of care, distance from care sites, 
transportation costs and long waiting times at the facility) (157). Optimizing the 
impact of effective treatment and prevention will require interventions to both 
expand the uptake of testing and improve linkage to confirmatory viral load testing 
and uptake of treatment.
The 2017 WHO Guidelines on hepatitis B and C testing recommended that all 
facility- and community-based hepatitis testing services adopt and implement 
strategies to enhance uptake of testing and linkage to care (strong recommendation, 
moderate quality of evidence) (3). In particular, the following evidence-based 
interventions should be considered to promote uptake of hepatitis testing and 
linkage to care and treatment initiation (conditional recommendation):
•  trained peer and lay health worker support in community-based settings 
(moderate quality of evidence);
•  clinician reminders to prompt provider-initiated, facility-based HCV testing in 
settings that have electronic records or analogous reminder systems (very low 
quality of evidence);
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•  provision of hepatitis testing as part of integrated services within a single facility, 
especially mental health/substance use (very low quality of evidence);
•  dried blood spot (DBS) specimens for NAT ± serology in some settings (low/
moderate quality of evidence).
Other approaches that may be considered to promote linkage include (8)
•  on-site single rapid diagnostic test (RDT) with same-day results;
•  reflex laboratory-based virological NAT of positive serology samples;
•  providing assistance with transport if the treatment centre is far from the 
testing site.
Specific policies can improve and monitor linkages between hepatitis testing and 
prevention, treatment and care services. Interventions that impact on multiple 
steps along the care continuum will generally be more resource efficient.
6.4 Integrated testing, care and treatment 
The goal of programme collaboration is to create integrated delivery systems that 
can facilitate access to hepatitis testing, treatment and other health services. There 
are three types of potential service integration:
1.  providing testing for HCV infection in different settings (e.g. in HIV/ART, TB, 
sexually transmitted infection [STI] or antenatal clinics);
2.  integrating the diagnosis of hepatitis with diagnostic platforms and laboratory 
services used for other infections;
3.  integrated service delivery of care, prevention and treatment (e.g. HCV care 
at harm reduction or HIV sites).
6.4.1 Providing testing for HCV infection in different settings
WHO already recommends integration of HIV testing into a range of other clinical 
services, such as services for TB, HIV/ART, maternal and child health, sexual and 
reproductive health (STI clinics), mental health and harm reduction programmes, 
migrant and refugee services, and in prisons (158). Integrating HCV and HIV 
testing will be particularly important in populations with high-risk behaviours for 
both infections, such as PWID, MSM and incarcerated persons who have a high 
prevalence of both HIV and HCV infection (159).
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The primary purpose of integration is to make HBV, HCV and HIV testing more 
convenient for people coming to health facilities, and so expand the reach and 
uptake of viral hepatitis testing. For the HCV-infected person, integration of 
hepatitis testing into other health services may facilitate addressing other health 
needs at the same time, thereby saving time and money. For the health system, 
integration may reduce duplication of services and improve coordination (e.g. in 
stock management of diagnostic assays).
6.4.2 Integrating the diagnosis of hepatitis with diagnostic 
platforms and laboratory services used for other infections
Combination integrated multidisease serological tests
The use of combination integrated blood- or oral-based multidisease assays allow 
for integrated testing of HIV, HBV and HCV. Using a single specimen improves the 
efficiency of testing programmes, especially in populations with a high prevalence 
of HIV/HCV or HBV/HCV coinfection. While not yet fully validated, preliminary 
results of these combination assays appear promising (160).
Shared use of HIV or TB multidisease platforms for HCV viral load testing
The introduction of multidisease testing devices (also known as polyvalent testing 
platforms) brings new opportunities for collaboration and integration, and can 
both increase access as well as provide significant system efficiencies, with cost-
savings. Countries with existing multidisease platforms for HIV viral load or TB 
testing or those that are planning for their introduction can consider collaboration 
and integration of HCV viral load testing (161). This includes both high-throughput 
laboratory-based instruments for HIV viral load measurement and point-of-care 
instruments such as GeneXpert for HIV and TB.
6.4.3 Integrated service delivery of care, prevention and treatment 
Increased access and rapid scale up of HCV treatment and care will require a 
significant change in the way that services are delivered. Where possible, HCV 
services (testing and DAA treatment) can integrate the public health system. In 
many cases, this integration goes down to primary health-care facilities. It makes 
use of existing HIV and harm reduction services (OST and/or needle exchange 
programmes) or prison health services to increase access, especially for PWID. 
Existing WHO guidance on delivery of effective OST programmes is available (5). 
Continuity of prevention and care is needed to ensure ongoing harm reduction 
measures and avoid reinfection, especially among PWID and MSM. Integration of 
services means not only provision of related services at a single setting, but also 
linking reporting systems to share information between settings and providers.
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6.5 Decentralized services
Decentralization of services refers to service delivery at peripheral health facilities, 
community-based venues and locations beyond hospital sites, bringing care 
nearer to patients’ homes. This may reduce transportation costs and waiting time 
experienced at central hospitals and, as a result, improve linkage to treatment 
and follow up. In high HIV-burden LMICs, the decentralization of HIV treatment 
services was a key factor in successful global scale up, improving uptake of both 
testing and treatment, and reducing loss to follow up (162, 163). In contrast, 
delivery of viral hepatitis testing and treatment has until recently generally 
relied on specialist-led centralized care models in hospital settings (164, 165). 
Decentralization of testing services will require access to quality-assured RDTs 
or collection and analysis of DBS specimens, good specimen referral networks, 
enhanced connectivity for return of results, and an electronic results system. 
Decentralized provision of care and treatment will be facilitated by use of a 
simplified algorithm (see summary algorithm in the Executive summary), access to 
pangenotypic regimens and a programme of staff training and supervision. There 
are now several examples of successful models of decentralized viral hepatitis 
testing and treatment services emerging in high-burden countries, including 
Mongolia and Egypt. Decentralization of services, however, may not always be 
appropriate for all settings, or acceptable to all clients, and the relative benefits 
should be assessed according to the context. Key requirements to deliver effective 
decentralized care are described below.
6.5.1 Task-sharing
Many countries affected by HCV infection face shortages of trained health workers 
and specialists in hepatitis management. Task-sharing is a pragmatic response 
to shortages of the health workforce to support decentralized care. It is strongly 
recommended by WHO in HIV care based on a comprehensive evidence base and 
has been widely adopted to expand access to HIV testing and treatment globally 
(91, 166). Effective task-sharing with non-specialists or nurses requires provision 
of appropriate training at the decentralized site, and access to additional support 
or referral to tertiary or specialist sites for more complex cases. 
6.5.2 Differentiated HCV care and treatment 
Currently, the majority of HCV care and treatment during this early phase of 
scale up is facility based, and not differentiated according to individual needs. 
Differentiated care is defined as a client-centred approach that simplifies and 
adapts services across the cascade, in ways that both serve the needs better of 
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those with more complex problems requiring prompt or specialized clinical care 
but also relieves overburdened hepatitis clinics in central hospitals. Based on an 
evidence-based differentiated care framework recommended by WHO and widely 
adopted in HIV treatment and care programmes, a similar approach is proposed 
to support decentralized management of HCV infection.
Broadly, three groups of HCV-infected persons with specific needs can be 
identified. Table 6.1 summarizes these three groups, their anticipated care needs, 
the most appropriate setting to deliver care and the type of provider needed. 
The majority of persons with HCV will have early-stage liver disease; they can be 
treated at facility level or potentially even in the community. Only a small proportion 
will require more intensive clinical or psychosocial support. However, this will vary 
considerably according to the epidemic profile of the country, and the maturity of 
the treatment response and diagnosis rate. 
1.  Persons clinically well and stable: this represents the majority of persons 
diagnosed, and includes those with no evidence of cirrhosis, serious 
comorbidities, mental health issues or active drug use; and the ability to 
comprehend issues of adherence and prevention messages. 
2.  Persons requiring more intensive clinical support: this includes persons 
presenting to care with advanced liver disease or serious comorbidities, 
previous treatment failure that requires either a more intensive or fast-tracked 
clinical and care package to manage life-threatening clinical problems and 
initiate treatment with more intensive monitoring. 
3.  Persons requiring more intensive psychosocial/mental health support, or 
intercultural or language support: this may include those with mental health 
issues, PWID, those with alcohol misuse, or adolescents requiring additional 
support and counselling. Migrant populations and Indigenous Peoples may 
also require more intensive intercultural or language support.
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TABLE 6.1 Potential differentiated care needs and approaches to viral hepatitis
Who?
HCV-infected persons 
category
What?
Care needs
Where?
Site
By whom?
Caregiver 
Clinically well and stable Standard care package: 
counselling, adherence 
support, treatment 
initiation and monitoring
Facility-based, 
including primary 
care or community-
based settings, and 
mobile/outreach
Physician or 
nurse
Advanced liver disease 
or serious comorbidities, 
hepatocellular cancer 
(HCC), previous treatment 
failure
Requiring more intensive 
clinical support and 
follow up: management 
of liver-related 
complications  
(e.g. variceal bleed, 
ascites, encephalopathy,  
HCC treatment)
Facility-based – 
hospital
Physician
Mental health issues, 
people who inject drugs or 
engage in alcohol misuse, 
adolescents, migrants
Requiring more 
intensive psychosocial/
mental health support, 
or intercultural and 
language support
Can be facility-based 
or community-based, 
harm reduction site
Physician and 
counsellor/peer 
support
6.6 Community engagement and peer support, 
including addressing stigma and discrimination in the 
general population
Peer-led interventions have been effective in increasing access, care and 
treatment, and supporting adherence to treatment, for both hepatitis and other 
infectious diseases particularly for marginalized population groups such as PWID 
(3, 167). In addition to providing services, peers can act as role models and offer 
non-judgemental support that may contribute to reducing stigma and improving 
the acceptability of services.
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6.7 Strategies for more efficient procurement and 
supply management of medicines and diagnostics
Access to DAAs for hepatitis C has improved since their initial registration in 2013 
(Table 6.2). In 2017, 62% of those infected with HCV lived in countries where 
generic medicines could be procured. Countries that made use of this possibility 
and registered multiple medicines from different manufacturers managed to 
achieve a major reduction in prices (4). However, initial progress in access to 
DAAs has been mostly for the sofosbuvir/ledipasvir and sofosbuvir/daclatasvir 
combinations (Table 6.2). Of these, sofosbuvir/daclatasvir is a pangenotypic 
regimen. With respect to the other two pangenotypic regimens, the innovator 
company has announced an access programme for sofosbuvir/velpatasvir. No 
information is available for glecaprevir/pibrentasvir. 
Key steps to increase the availability of DAA and diagnostics at country level 
include the following (4):
1.  Selecting products: formulating national testing and treatment guidelines 
that specify which medicines and diagnostic assays should be used. WHO-
prequalified products are listed at: http://www.who.int/diagnostics_laboratory/
evaluations/PQ_list/en/ 
  http://www.who.int/medicines/news/2017/1st_generic-hepCprequalified_
active_ingredient/en/ 
2.  Determining whether generic medicines are available in the country: if 
DAAs are not protected by a patent or if the country is included in the respective 
license agreement, procurement of generic medicines from various sources 
is possible. Otherwise, the country needs to enter into price negotiations with 
the originator company or if this does not yield satisfactory results, use the 
flexibilities contained in the World Trade Organization (WTO) Agreement on 
Trade Related Intellectual Property Rights (4).
3.  Registration and inclusion in the national essential medicines list: DAAs 
need to be registered with the national regulatory authority and included in the 
national essential medicines list. If access to generic medicines is possible, 
registration of products from as many manufacturers as possible will increase 
competition and lower prices.
4.  Quantification and forecasting of demand for commodities: to estimate the 
volume of products required to meet programme demand, managers need 
to estimate the size of the infected population in need of treatment and the 
expected rate of scale up for testing and treatment activities. 
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5.  Procurement of commodities: procurement mechanisms can include (i) a 
competitive tendering process in case of registration of multiple manufacturers 
of generic medicines or (ii) price/volume negotiation with the originators if 
generic medicines cannot be procured. A pooled procurement mechanism 
(e.g. Strategic Fund of the Pan American Health Organization) is another option 
for economies of scale in procurement of commodities, including diagnostics.
WHO tools are also available to estimate the cost–effectiveness of HCV treatment 
in individual countries (http://tool.hepccalculator.org/) and to procure diagnostics.
(http://www.who.int/diagnostics_laboratory/publications/procurement/en/). 
TABLE 6.2 Characteristics of available pangenotypic and non-pangenotypic DAAs
Pangenotypic regimens Sofosbuvir/
ledipasvir
Sofosbuvir/
velpatasvir
Sofosbuvir/
daclatasvir
Glecaprevir/
pibrentasvir
Efficacy in 
infection with HCV 
genotypes 1–6 
Pangenotypic Pangenotypic Pangenotypic Genotype  
dependent
Tolerability High High High High
Registration status 
in low- and middle-
income countries 
Very low Low Very low Low
Access plans in 
low- and middle-
income countries 
In development Large number 
of countries 
included in 
voluntary license 
agreements
No information 
available
Large proportion 
of countries 
included in 
voluntary license 
agreements 
Acceptability by 
health providers
Highest Highest Highest High
Health system 
costs (genotyping; 
laboratory; 
personnel)
Low Low Low High 
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6.8 Data systems for monitoring the quality and 
cascade of care 
WHO has developed a monitoring and evaluation framework to enable Member 
States to report on hepatitis elimination (73). Three indicators address the cascade 
of care, including the proportion of infected persons diagnosed (core indicator 
C6b), treatment initiation rate (core indicator C7b) and the proportion of those 
treated who are cured (C8b). In an initial assessment phase, triangulation of data 
from different sources may be used to generate an initial estimate of the three core 
indicators of the cascade of care. In the longer term, estimating the indicators of 
the cascade of care requires a database of HCV-infected persons based on simple 
individuals’ records. Such databases can be integrated with those used to monitor 
HIV and/or TB treatment as appropriate. 
CHAPTER 7. PUBLIC HEALTH  
CONSIDERATIONS FOR  
SPECIFIC POPULATIONS
The two considerations in the box below are existing formal WHO recommendations 
that address focused testing for HBV and HCV infection and harm reduction 
for PWID.
Existing recommendation from the 2017 HBV and HCV testing guidelines (3)
In all settings (and regardless of whether delivered through facility- or community-based  
testing), it is recommended that serological testing for HCV antibody (anti-HCV)1 or HBsAg be 
offered with linkage to prevention, care and treatment services to the following individuals:
•  Adults and adolescents from populations most affected by HCV infection2 (i.e. who are 
either part of a population with high HCV seroprevalence or who have a history of exposure 
and/or high-risk behaviours for HCV infection);
•  Adults, adolescents and children with a clinical suspicion of chronic viral hepatitis3  
(i.e. symptoms, signs, laboratory markers).
(Strong recommendation, low quality of evidence)
Note: Periodic retesting using HCV nucleic acid tests (NAT) should be considered for those with ongoing risk of acquisition  
or reinfection.
1  This may include fourth-generation combined antibody/antigen assays.
2  Includes those who are either part of a population with higher seroprevalence (e.g. some mobile/migrant populations 
from high/intermediate endemic countries, and certain indigenous populations) or who have a history of exposure or 
high-risk behaviours for HCV infection (e.g. PWID, people in prisons and other closed settings, MSM and sex workers, 
and HIV-infected persons, children of mothers with chronic infection, especially if HIV-coinfected).
3  Features that may indicate underlying chronic HCV infection include clinical evidence of existing liver disease, such as 
cirrhosis or HCC, or where there is unexplained liver disease, including abnormal liver function tests or liver ultrasound.
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All other considerations discussed in this chapter are based on good 
practice principles.
7.1 People who inject drugs
7.1.1 Background
In 2017, there were an estimated 15.6 million PWID aged 15–64 years (168). 
PWID are at risk for infections, including HCV infection (169), mental health 
issues, psychosocial challenges, contact with law enforcement agencies (170) 
and premature death (171). 
Fifty-two per cent of PWID (95% UI: 42–62) have serological evidence of past 
or present HCV infection (anti-HCV positive) and 9% (95% CI: 5–13) have HBV 
infection (HBsAg positive) (168). However, many infected PWID are unaware 
of their diagnosis and few initiate treatment (172), because of criminalization, 
discrimination, unstable housing and stigma in health-care settings (173). Around 
58% of PWID have a history of incarceration (168). PWID are also at increased risk 
of new HCV infection and reinfection (47, 172). They require prevention services 
to reduce the risk of infection and reinfection after a cure (174). 
7.1.2 Service delivery considerations
Prevention services and reducing harm from injecting drug use
•  High-coverage harm reduction programmes for PWID to prevent HCV 
transmission and reinfection. WHO already recommends both needle and 
syringe distribution and OST (5) as effective interventions for HIV prevention, 
but only a high coverage of these interventions also prevents HCV transmission 
(175) (176).
•  Education of PWID. Harm reduction interventions educate on prevention and 
provide access to sterile equipment. OST reduces the frequency of injection 
(177), treats underlying dependence and helps to prevent overdose. 
•  Access to low dead-space syringes. NSPs make use of low dead-space 
syringes (178). 
Existing recommendation from the 2016 updated guidelines on HIV prevention, diagnosis, 
treatment and care for key populations (5)
All people from key populations who are dependent on opioids should be offered and have 
access to opioid substitution therapy.
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Testing
Routine targeted testing of all PWID for HCV, HBV and HIV infection was 
recommended in the 2017 WHO testing guidelines (3). Testing and treatment 
in drug dependency services or prisons is cost effective in high-income settings 
(132, 179). Specific interventions improve coverage (180). Regular testing for 
HCV is relevant to uninfected PWID, those cured, and those who had cleared the 
virus spontaneously. Previously infected persons are tested directly with HCV RNA 
as they will remain anti-HCV positive after the first infection (181). 
Linkage and care
Following diagnosis, PWID can be referred to appropriate services. Specific 
interventions can improve linkage (180) to a package of care that includes 
treatment (182) and addresses other medical and/or psychosocial issues. Peer 
interventions and integrated comprehensive HCV care may increase acceptability, 
uptake and adherence. It can reduce injecting drug use and improve injection 
practices (183). See the WHO ASSIST package – guidance on brief behavioural 
interventions for substance use (184).
Treatment
Limited data (185–190) indicate high SVR rates among PWID treated with DAAs 
for HCV infection. DDIs can take place between both prescribed and non-
prescribed drugs.
7.2 People in prisons and other closed settings
7.2.1 Background
Worldwide, at any given time, an estimated 10 million people are incarcerated 
(191). HCV infection is more common among incarcerated persons or those who 
have previously spent time in correctional facilities. A meta-analysis reported 
a global prevalence of HCV infection of 26% among general detainees, and of 
64% among detainees with a history of injecting drug use (192). Incidence was 
estimated at 1·4 per 100 person-years, rising to 16·4 per 100 person-years in those 
with a history of injecting drug use (192). Overall, 58% of PWID have a history of 
incarceration and 56–90% of PWID would be incarcerated at some stage (168). 
Criminalization of drug use may explain the frequency of HCV infection in prisons 
and other closed settings. One in every five prisoners is held for drug-related 
charges (170). Transmission continues in closed settings because of injecting 
drug use, tattooing (193) and possibly sexual transmission among men. However, 
OST is available in the prisons of only 52 countries, and only eight countries have 
at least one NSP within a closed setting (194).
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7.2.2 Service delivery considerations
Prisons are an opportunity to offer prevention, testing, care and treatment services 
to marginalized populations that otherwise might have difficulty in accessing care.
•  Expansion of NSP and OST coverage. The United Nations 2016 General 
Assembly Special Session (UNGASS) on Drugs called for non-discriminatory 
access to “medication-assisted therapy”, including access in prisons and other 
custodial settings, and suggested that national authorities consider making 
NSPs available in custodial settings (195). 
•  Provision of DAAs in prisons. The short duration of DAA treatment allows 
delivery in closed settings, including through task-sharing with nurses (196). 
•  Negative consequences of testing in prison. Mandatory or coercive testing, 
segregation of prisoners, and refusal of treatment have been reported.
•  Continuation of prevention, testing and treatment services available in 
the community during detention and vice versa. Persons who were ever 
incarcerated, particularly PWID, are likely to return to prison. Health services 
in prisons differ from those in the community. Medical care may be interrupted 
because of incarceration and upon return to the community (197, 198). People 
receiving community-based OST, as well as treatment for HIV and HCV, suffer 
from these disruptions of care (199, 200). 
7.3 Indigenous Peoples
7.3.1 Background
Viral hepatitis disproportionately affects Indigenous Peoples in most parts of the 
world (9, 201). The world’s 370 million Indigenous Peoples face displacement, 
dispossession, loss of livelihood, systematic racism as well as abuse and lack of 
recognition, threatening the sacred relation between Indigenous Peoples and their 
landbase. Poverty as well as large health disparities are common among Indigenous 
Peoples. Access to health services is often further hampered by the remoteness of 
their communities or language and cultural barriers. In some countries, including 
Canada and Australia, rates of incarceration and injecting drug use are high in 
Indigenous Peoples, further increasing the risk of HCV acquisition (202, 203). 
7.3.2 Service delivery considerations
The United Nations Declaration on the Rights of Indigenous Peoples highlights 
several key considerations for the health of Indigenous Peoples. Indigenous 
Peoples have the right to be actively involved in developing and determining the 
health programmes that affect them, and to administer, as far as possible, such 
programmes through their own institutions. Indigenous Peoples also have the 
55
right to access, without any discrimination, to all social and health services (204). 
Specific considerations in delivering HCV prevention, diagnosis and treatment 
services include: 
•  employing and training Indigenous staff in HCV prevention, diagnosis 
and treatment; 
•  catering to specific language or cultural needs, e.g. gender-specific 
service provision;
•  engaging with local Indigenous representatives to gain endorsement 
and acceptance;
•  consulting with community members to address concerns or provide 
information;
• engaging with the community to increase availability of treatment.
7.4 Men who have sex with men 
7.4.1 Background
HCV is not commonly transmitted through unprotected sexual intercourse among 
monogamous heterosexual partners (205–208). However, sexual practices that 
cause mucosal trauma, group sex, chemSex (the practice of non-injection and 
injection use of certain drugs before and during sex), and the presence of HIV 
infection increase sexual transmission of HCV among MSM (52, 209–211). Non-
injecting HIV-infected MSM populations have a high incidence of HCV infection 
(212). Transmission increases with unprotected receptive anal intercourse, 
ulcerative STI lesions and lower CD4 counts (213). The implementation of HIV 
pre-exposure prophylaxis (PrEP) among sexually active HIV-negative MSM was 
also followed by reports of a rise in HCV incidence (214).
7.4.2 Service delivery considerations
•  The 2017 WHO testing guidelines recommend regular HCV testing for MSM 
(3). Information can be provided on modes of transmission during male-to-
male sex. 
•  Treatment of HCV-infected MSM with DAA. Specific treatment of HCV/HIV-
positive MSM may prevent onward transmission of HCV. Attention must be paid 
to DDIs with DAAs for persons on ART (see section 5.1.1).
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7.5 Sex workers
7.5.1 Background
Sex workers of both genders are more likely to have HCV infection than the general 
population for a variety of reasons, such as higher rates of substance use and drug 
injecting, higher prevalence of HIV infection and more exposure to HCV (9).
7.5.2 Service delivery considerations
Various health and welfare needs may facilitate the engagement of sex workers 
in care. 
•  Strategies to facilitate engagement in care. This may include outreach, 
on-site testing services, peer-based interventions, and linkage to other health 
and welfare services. 
•  Linkage and referral to appropriate services upon request where substance 
use, including alcohol and injecting drug use, is present. This involves 
providing access to harm reduction interventions such as OST and NSP, 
where necessary.
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